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ACCP  American College of Chest Physicians
AUC   area under the curve
BMI  body mass index
BPM  beats per minute
CI   confidence interval
COPD   chronic obstructive pulmonary disease 
CPR  cardiopulmonary resuscitation
CT   computed tomography
CTEPH  chronic thromboembolic pulmonary hypertension
CTPA  computed tomography pulmonary angiography
DVT  deep vein thrombosis
ECG  electrocardiography
ED   emergency department
ESC  European Society of Cardiology
GP   general practitioner
HR   hazard ratio
ICU   intensive care unit
INR   international normalized ratio
IRB   institutional review board
ISTH  International Society of Thrombosis and Haemostasis
IU   international units
LMWH  low molecular weight heparin
LV    left ventricle
NA   not applicable
NOACs  new oral anticoagulants
NT-proBNP  N-terminal pro-Brain Natriuretic Peptide
NYHA  New York Heart Association
OAC  oral anticoagulants
OR   odds ratio
PE   pulmonary embolism
PESI  pulmonary embolism severity index
ROC   receiver operating characteristics
RV    right ventricle
RVD  right ventricular dysfunction
SBP  systolic blood pressure
SD   standard deviation 
SE   standard error
sPESI   simplified pulmonary embolism severity index
TTE  transthoracic echocardiography 
US   ultrasonography
VCF  vena cava filter
VKA  vitamin K antagonists
V/Q scan  ventilation-perfusion scintigraphy








For more than 100 years it has been recognized that pulmonary embolism (PE), a condition 
caused by the formation of a thrombus in the pulmonary arteries, could lead to severe dys-
pnea.1 However, no effective treatment was available until the first part of the 20th century 
and the majority of the patients with PE died.2 
It was not until 1938 that the first claims of successful anticoagulant treatment with hepa-
rin were published.3,4 However, there was one disadvantage of the use of heparin: it had to 
be administered intravenously. Because of the intravenous administration, PE patients had to 
stay in the hospital and therefore could only be treated for a short period of time. A discovery 
by two veterinarians in 1920 was the start for the development of the first anticoagulant for 
long term treatment. They observed that cattle that had eaten spoiled hay suffered from 
massive hemorrhage.5 This lead to the discovery of a substance from the sweet clover, named 
coumarin, which was responsible for the anticoagulant mechanism that caused the bleeding 
in the cattle. Coumarin was extracted in the laboratory for medicinal use to prevent further 
thrombus formation in patients with PE. Because coumarin was administered orally, from this 
point in time patients could be treated out of the hospital and the duration of anticoagulant 
treatment could be prolonged. 
Another breakthrough came in 1960, when the first clinical trial investigating the use of 
heparin combined with coumarin was published.2 This trial demonstrated that the prognosis 
of patients with PE improved largely upon treatment with the combination of intravenous 
unfractionated heparin and coumarin. Afterwards, the treatment of PE patients with the com-
bination of heparin and coumarin was considered standard patient care for many decades.3 
The next large change in anticoagulant management came with the introduction of low-
molecular weight heparin (LMWH), which could be administered subcutaneously and was at 
least as effective as unfractionated heparin administered intravenously.6 Because unfraction-
ated heparin had to be administered intravenously, patients who were diagnosed with PE 
were admitted to the hospital for at least five days. After the introduction of LMWH, the dura-
tion of hospital admission shortened over the years.7 In the last decade small observational 
studies have been published, which gave a first indication towards the safety and efficacy of 
the outpatient treatment of PE patients.8-10 The first systematic review on outpatient treat-
ment of PE patients indicated that the quality of those observational studies was too low to 
incorporate outpatient treatment of patients with PE in standard patient care.11
Over the last years, more solid evidence on the safety of outpatient treatment in PE pa-
tients is accumulating.12 In the first part of this thesis more recent publications on outpatient 
treatment of patients with PE are extensively discussed. The results of the Hestia study, a 
prospective multicenter cohort study on outpatient treatment of PE patients, which we 
performed in conjunction with 12 hospitals in The Netherlands, are presented in chapter 2 
and 3. In chapter 4, the results of all available studies on outpatient treatment of PE patients 
in the literature are summarized in a meta-analysis. 
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The second aim of this thesis was to compare methods for risk stratification, which 
discriminate low from high risk PE patients, in order to treat the low risk patients at home 
safely.13 Several methods for risk stratification are available14: methods based on clinical signs 
and symptoms 15,16, laboratory values17,18 or imaging modalities19,20. In the Hestia study, de-
scribed in chapter 2, the Hestia criteria were used to select low risk PE patients for outpatient 
treatment. The Hestia criteria were compared to two other methods for risk stratification, the 
Pulmonary Embolism Severity Index (PESI) and the assessment of right ventricular dysfunc-
tion on computed tomography and the results of these analyses are found in chapters 5 and 
6. Chapter 7 describes the potential role of repeated measurements of the laboratory value 
NT-proBNP in selecting patients with PE for outpatient treatment or early discharge. Finally, 
in chapters 8 and 9 the prognosis of patients with PE and different baseline characteristics 
is described: patients with provoked PE versus unprovoked PE and patients presenting to a 
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Traditionally, patients with pulmonary embolism (PE) are initially treated in the hospital with 
low molecular weight heparin (LMWH). The results of a few small non-randomized studies 
suggest that in selected patients with proven PE outpatient treatment is potentially feasible 
and safe. The objective of this study was to evaluate the efficacy and safety of outpatient 
treatment according to predefined criteria in patients with acute PE.
Methods
Prospective cohort study of patients with objectively proven acute pulmonary embolism, 
conducted in 12 hospitals in the Netherlands between 2008 and 2010. Patients with acute PE 
were triaged with the predefined criteria for eligibility for outpatient treatment starting with 
LMWH (Nadroparin), followed by vitamin K antagonists. All patients eligible for outpatient 
treatment were sent home either immediately or within 24 hours after PE was objectively 
diagnosed. Outpatient treatment was evaluated with respect to recurrent venous thrombo-
embolism (VTE), including PE or deep venous thrombosis (DVT), major hemorrhage and total 
mortality during 3 months follow up. 
Results 
Of 297 included patients, who all completed follow-up, six patients (2.0%; 95% confidence 
interval (CI), 0.8-4.3) had recurrent VTE (five PE (1.7%), one DVT (0.3 %)). Three patients (1.0%, 
95% CI 0.2-2.9) died during 3 months follow-up, none of fatal PE. Two patients had a major 
bleeding event, of which one fatal intracranial bleeding (0.7 %, 95% CI 0.08%-2.4%).
Conclusion
Patients with PE selected for outpatient treatment with predefined criteria can be treated 
with anticoagulants on outpatient basis. 
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Introduction
Pulmonary embolism (PE) is a common condition with a variable clinical presentation rang-
ing from patients with minor thoracic pain to patients with fatal PE.1 The risk for mortality 
and other serious events differs. Patients presenting with symptoms of shock have a high risk 
for short-term mortality of approximately 30%, while patients who maintain a normal blood 
pressure have a risk of PE-attributable mortality of 2-6%.2-4 Patients with a risk of short-term 
mortality of less than 1% are typically considered to be low-risk patients and these patients 
may potentially be amenable for outpatient treatment.4
In patients with deep vein thrombosis (DVT) treatment out of the hospital with low-
molecular-weight heparin (LMWH) followed by vitamin K antagonists (VKAs) is commonly 
accepted.5,6 Since these patients have a low risk of developing (fatal) PE, outpatient treatment 
of patients with DVT has become worldwide standard of care.7
In the last decade, several small observational studies on outpatient treatment in PE have 
been published.8-21 These studies on outpatient treatment include 9 prospective and 5 retro-
spective studies with the largest prospective study containing 152 patients entirely treated 
at home. The majority of the prospective studies used simple bedside criteria for selection of 
patients for outpatient treatment.9,10,12,19-21 In these studies no PE-related mortality occurred, 
only one patient died of major bleeding and non-fatal recurrence rates of venous thrombo-
embolism (VTE) varied from 0% - 6.2%.22   
The objective of the Hestia Study was to confirm the results of these small cohort studies 
in a large study and provide proof that incidences of VTE recurrence, major bleeding and 
mortality are very low in patients selected by a simple set of exclusion criteria. 
Methods
Design overview
The Hestia study was a multicenter prospective cohort study in patients with acute PE who 
were selected for outpatient treatment if they did not apply to a predefined set of exclusion 
criteria. We evaluated the efficacy and safety of out of hospital anticoagulant treatment with 
LMWH followed by VKAs for at least 3 months. The protocol was approved by the institutional 
review board of each participating hospital. The data were collected and stored in the data-
base by the investigators. All suspected outcome events were classified by an independent 
central adjudication committee, whose members were not participating in the study. It was 
predefined that an independent data and safety monitoring board periodically reviewed the 
studies’ outcomes after every 50 included patients and advised the investigators. The manu-





Patients were recruited from 12 hospitals in the Netherlands (three academic and nine 
non-academic hospitals). Consecutive patients, applying to the following inclusion criteria, 
were potentially eligible: over 18 years of age with objectively proven acute PE presenting to 
the Emergency Department or outpatient clinic. Patients with asymptomatic or chronic PE, 
defined as duration of symptoms existing longer than 14 days and no acute worsening within 
the last 14 days, were not included. Patients were triaged according to predefined exclusion 
criteria (Exclusion criteria; Table 1). This checklist with 11 items can be used as a bedside 
test and can be completed within 5 minutes. Patients could not be treated at home if one of 
the exclusion criteria (Table 1) were fulfilled; otherwise patients were eligible for outpatient 
treatment.  
For study reasons additional exclusion criteria were the following: impossibility for the 
required 3 months follow-up (e.g. no fixed address, foreign citizen) or life expectancy less 
than 3 months. After giving written informed consent and starting treatment with LMWH, 
patients were sent home either immediately, or within 24 hours after the diagnosis of PE for 
out-of-hospital treatment. 
Table 1: Exclusion criteria for outpatient treatment
Is the patient hemodynamically instable?*
Is thrombolysis or embolectomy necessary?
Active bleeding or high risk for bleeding?**
More than 24 hours of oxygen supply to maintain oxygen saturation > 90%?
Is pulmonary embolism diagnosed during anticoagulant treatment?
Severe pain needing intravenous pain medication for more than 24 hours?
Medical or social reason for treatment in the hospital for more than 24 hours? (infection, malignancy, no support system ie)
Does the patient have a creatinine clearance of less than 30 ml/min?***
Does the patient have severe liver impairment?****
Is the patient pregnant?
Does the patient have a documented history of heparin-induced thrombocytopenia?
*Include the following criteria, but are left to the discretion of the investigator: systolic blood pressure < 100 
mmHg with heart rate > 100 beats per minute; condition requiring admission to an intensive care unit
**Gastrointestinal bleeding in the preceding 14 days, recent stroke (less than 4 weeks ago), recent operation 
(less than 2 weeks ago), bleeding disorder or thrombocytopenia (platelet count < 75 x 109/L), uncontrolled 
hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg)
*** Calculated creatinine clearance according to the Cockroft-Gault formula
****Left to the discretion of the physician
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Interventions
Patients were treated with standard anticoagulant therapy according to international guide-
lines.7 Initial treatment consisted of once daily subcutaneous LMWH Nadroparin corrected for 
body weight (11400 IU for body weight < 70 kg.; 15200 IU for body weight ≥ 70 kg). The first 
dose of LMWH was given at the emergency department under supervision of a nurse. The 
patient or a family member was instructed how to administer LMWH at home. On the same 
day VKAs (phenprocoumon or acenocoumarol) were started and titrated to an INR between 
2.0 and 3.0. The INR was monitored and VKA was titrated by the Dutch Thrombosis Services. 
LMWH was continued for at least 5 days and was stopped by the Thrombosis Services if the 
INR was in the target range for 2 consecutive days. Patients with active malignancy could 
be treated with LMWH alone during a 6 month period, according to the guidelines.7 This 
treatment decision was left to the treating physician.
Outcomes and Follow-up 
All patients were seen at the outpatient clinic at 1 week and 3 months after initial presenta-
tion. After 6 weeks follow-up an additional telephone contact was planned. At each contact 
the presence of clinical signs and symptoms suggestive of recurrent VTE or bleeding were 
assessed. Patients were instructed to contact their specialist before the fixed appointments 
for objective testing whenever clinical signs or symptoms suggestive of recurrent PE, DVT or 
if a bleeding complication occurred. 
The primary endpoint was objectively proven recurrent VTE during 3 months follow-up. 
Major bleeding and death within 3 months were defined as secondary endpoints. 
Symptomatic recurrent VTE was the main efficacy parameter. Recurrent VTE was consid-
ered present if recurrent PE or DVT were documented objectively, or in case of death in which 
PE could not be confidently ruled out as a contributing cause. The objective criterion for the 
diagnosis of recurrent PE was a new intraluminal filling defect on spiral CT or pulmonary 
angiography; cut-off of contrast material in a vessel > 2.5 mm in diameter on pulmonary 
angiography; a new perfusion defect involving at least 75% of a segment, with correspond-
ing normal ventilation (i.e. a high probability lung scan); a new non-diagnostic lung scan 
accompanied by documentation of DVT by ultrasonography or venography; or confirmation 
of a new PE at autopsy. The objective criterion of a new DVT was a –new-, non-compressible 
venous segment or a substantial increase (> 4 mm) in the diameter of the thrombus during 
full compression in a previously abnormal segment on ultrasonography or a new intraluminal 
filling defect on contrast venography. 
Major bleeding was the main safety outcome and was defined as fatal bleeding, and/or 
symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, 
retroperitoneal, intra-articular, pericardial or intramuscular with compartment syndrome, 
and/or bleeding causing a fall in hemoglobin level of more than 2.0 g/dL (1.3 mmol/L), or 
leading to transfusion of more than two units of whole blood or red cells.23 Clinically relevant 
Chapter 2
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bleeding episodes, not qualifying as major bleeding, were classified as clinically relevant 
non-major bleeding (e.g. epistaxis that required intervention, large hematoma visible on the 
skin, or spontaneous macroscopic hematuria). 
Mortality was defined as death due to recurrent PE (fatal PE), fatal bleeding, cancer, or 
another established diagnosis. Information about the cause of death was obtained from 
autopsy reports or from a clinical report. 
An independent adjudication committee consisting of two physicians not involved in 
the study evaluated all possible endpoints i.e. recurrent VTE, major bleeding or death. Any 
dispute was resolved by a third opinion. If no objective imaging of a suspected event was 
obtained, the event was evaluated on clinical grounds by the adjudication committee. 
Statistical analysis
The primary endpoint is symptomatic recurrent VTE during 3 months of follow-up. We con-
sidered outpatient treatment to be effective if the upper limit of the 95% confidence interval 
(CI) of the incidence of recurrent VTE did not exceed a predefined margin. This predefined 
margin was based on incidences reported in literature.6,24 It was stated that VTE recurrence 
rates of patients treated at home should not be higher than rates found in patients treated 
in the hospital. Incidences of recurrent VTE in the literature are reported up to 7%.6,25 We 
therefore defined outpatient treatment according to the predefined criteria to be effective if 
the upper limit of the 95% CI did not exceed the 7%.
A power calculation was performed assuming an observed VTE recurrence in the study 
population of 3%.24 To obtain an estimate of the incidence with a CI below 7% a sample size 
of 257 patients was needed to achieve a power of 0.91 (one-sided binomial test). Allowing for 
a drop-out rate of 10%, a total of 280 patients with PE eligible for outpatient treatment had 
to be included. Exact 95% CIs were calculated around the observed incidences with Fisher’s 
Exact Test. SPSS software version 17.0 (SPSS Inc, Chicago, IL) was used for all analysis. The 
analysis was performed according to the intention to treat principle.   
Results
Study patients
Between May 2008 and April 2010 a total of 581 consecutive patients with acute PE were 
screened with the exclusion criteria for outpatient treatment, of which 243 were not eligible 
for outpatient treatment according to the criteria described in Figure 1.
A total of 338 patients were eligible for outpatient treatment, of which 41 patients were 
excluded for study reasons. This resulted in a total study population of 297 (51%) patients 
treated as outpatients (Figure 1). Some of the patients (23%) were admitted to the hospital 
for less than 24 hours, mainly because CT scanning was not available at night. The mean dura-
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tion of hospital admission in these patients was 19 hours. The clinical baseline characteristics 
of these patients are shown in Table 2. The mean age was 55 years and 26% of patients were 
older than 65 years, 58% of the patients were male and 9% had an active malignancy. 
Treatment and follow-up
All patients were treated with LMWH for at least 5 days, except for one patient, who only 
received 4 days of LMWH treatment because of hemoptysis. In another patient the LMWH 
treatment protocol was violated. This patient received the first dose of LWMH on the emer-
gency department, but he did not continue the treatment at home. Although he finally re-
ceived LMWH for at least 5 days, the LMWH treatment was interrupted for 48 hours during the 
second and third day after the index event. In the majority of patients, initial LMWH therapy 
was followed by VKA treatment (Table 2). Of the patients, 6.1% were treated with long term 
LMWH treatment alone because of malignancies or known allergy to VKA. For three patients 
(1.0%) information about the type and duration of anticoagulant treatment was missing. The 
3-month follow-up was completed for all patients.
Figure 1: Flow-chart
581 patients screened with
confirmed PE*
Excluded: N=243
Reasons for hospital admission**:
•Hemodynamically unstable N=30(12%)
•Thrombolysis*** N=5 (2%)
•High bleeding risk N=14 (6%)
•Oxygen supply N= 73 (30%)
•Intravenous pain medication N= 15 (6%)
•PE during OAC therapy N= 9 (4%)






•Severe liver impairment N=1
•Pregnancy N=1
•Other N=14
•Social reasons N= 24 (10%)
•Unknown N=10 (4%)
338 eligible patients
297 patients treated at home 
(51%)
Excluded: N=41
Exclusion for study reasons:
• Life expectancy < 3 mo N=2 
• Refusal of participation N=26
• No follow-up possible N=9
• Previous participation N=4
  
* Meeting inclusion criteria: outpatients older than 18 years with acute symptomatic objectively confirmed PE 
** Most important exclusion criterion 
*** Thrombolysis for other reasons than hemodynamic instability




Efficacy during the first week of treatment
One patient had recurrent PE during the first week (0.3% 95% CI 0.008-1.9%; Table 3). In this 
patient the LMWH treatment protocol had been violated (described above), because he 
did not use LMWH at home. He returned to the hospital at day 3 with increasing dyspnea; 
although no repeat CT scan was performed, it was adjudicated as an extension of the initial 
PE. He was admitted to the hospital for adequate anticoagulant therapy with therapeutic 
doses of LWMH and VKAs (Table 4). None of the patients, receiving adequate anticoagulant 
treatment, experienced a recurrent VTE event within 7 days of the initial event. No patient 
died of fatal PE during this period.
Efficacy during further follow-up 
Between the second week and 3 months follow-up, another five patients had recurrent VTE: 
recurrent PE in four patients and DVT in one patient (Table 3).
During the whole study period of 3 months follow-up six patients (2.0 %; 95% CI 0.8-4.3%) 
had a recurrent VTE, one of whom (0.3 %; 95% CI 0.008.-1.9%) had an objectively proven 
recurrent DVT, and five of whom (1.7%; 95% CI 0.5-3.9%) had recurrent PE, adjudicated on 
clinical grounds. In five of six patients adjudicated as having recurrent VTE anticoagulant 
Table 2. Baseline characteristics of study patients (n=297)
Age (years) 55 (15)
Age ≥ 65 yr 78 (26)
Male gender 172 (58)
BMI (kg/m2) 27 (5)
Duration of complaints (days) 4 (3)
Immobilization > 3 days or surgery < 4 weeks 27 (9.1)
Paralysis, paresis or plaster cast lower limbs 10 (3.4)
Estrogen use 47 (16)
Active malignancy 28 (9.4)
Heart failure with therapy 1 (0.3)
COPD with therapy 11 (3.7)
History of VTE 74 (25)
Unprovoked VTE* 207 (70)
LMWH + VKA** 276 (93)
Duration of LMWH usage (days) 9 (4)
LMWH continued 18 (6.1)
Categorical data are displayed as No (%). Numerical data are displayed as means (standard deviation). 
*Unprovoked VTE is defined as venous thromboembolism without presence of one of the following provoking 
factors: estrogen use, immobilization more than 3 days or operation in the last month or active malignancy. No 
thrombophilia testing was done. LMWH = low molecular weight heparin, VKA = vitamin K antagonists, VTE= 
venous thromboembolism, COPD = chronic obstructive pulmonary disease. ** Data on treatment were missing 
in N=3 (1.0%) 
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Table 3. Adverse clinical outcome during three months follow-up (N=297)
Clinical outcome Number Percentage
(95% CI)
Total recurrences 6 2.0 (0.75 – 4.3)
Fatal recurrent PE 0 0 (0-1.2)
Non-fatal recurrent PE 5 1.7 (0.55-3.9)
Non-fatal recurrent DVT 1 0.34 (0.0082-1.9)
Major bleeding complications 2 0.67 (0.082-2.4)
Fatal bleeding 1 0.34 (0.0082-1.9)
Non-fatal major bleeding 1 0.34 (0.0082-1.9)
Clinically relevant non-major bleeding 15 5.1 (2.9-8.2)
All cause mortality 3 1.0 (0.21-2.9)
PE = pulmonary embolism, DVT = deep vein thrombosis, CI=confidence interval
Table 4. Description of adverse clinical outcome during 3 months of follow-up
Recurrent VTE (n=6)
Gender Age Complaints Day Imaging Adverse event Brief description







Patient did not administer LMWH 
at home, complaints of dyspnea 
increased and he was admitted for 
administration of LMWH until INR 
was in target range







Admission for observation. 
Acenocoumarol was switched 
to Phenprocoumon to achieve 
increased stability of INR levels.







LMWH dosage was increased 
from 15200 IU once daily to 22800 
IU once daily (BMI 40 kg/m2). 
Admission until INR was stable in 
target range.







Admission for recurrent PE during 
inadequate INR level (1.5), LMWH 
treatment until INR was in target 
range
Female 55 Recurrent DVT 48 US: extension of 
thrombus from 
calf vein to iliac 
vein level   
Objectively proven 
recurrent DVT
Admission for recurrent DVT in 
patient with malignancy, increasing 
dosage of LMWH from 11400 IU 
once daily to 19000 IU once daily.







Recurrent PE during inadequate 
VKA therapy (INR 1.4), LMWH 




treatment was altered. The details are given in Table 4. None of the recurrent VTE events was 
fatal and all patients recovered completely (Table 4). 
Safety
Two patients (0.7%; 95% CI 0.08-2.4%) had a major bleeding episode (Table 3). One patient 
had a fatal intracranial bleeding at day 7. This intracranial bleeding started while she was in 
the outpatient clinic for a predefined appointment; she died within 24 hours. The second 
patient had a large abdominal muscle hematoma accompanied with a drop in hemoglobin 
level of 2.5 mmol/L at day 14, for which a short observation on the intensive care unit was 
needed; this patient recovered completely. Clinically relevant non-major bleeding occurred 
in 15 patients (5.1%; 95% CI 2.9-8.2%). These non–major clinically relevant bleeds occurred 
between day 1 and day 66 (median, day 24) and consisted of five patients with large skin 
hematomas, six patients with macroscopic hematuria, three patients with hemoptysis and 
one patient with an ovary bleeding without significant drop in hemoglobin. In three patients 
with clinically relevant non-major bleeding anticoagulant treatment was interrupted for 1 
day: in one patient with hemoptysis, in one patient with a large skin hematoma and in the 
patient with the ovary bleeding.
Mortality
Three patients (1.0%; 95% CI 0.2-2.9%) died during the study (Table 3). One patient died of 
fatal intracranial bleeding at day 7, confirmed by autopsy. The cause of mortality in the two 
Table 4. Description of adverse clinical outcome during 3 months of follow-up (continued)
Major bleeding (n=2)
Gender Age Adverse event Day Imaging Brief description
Female 54 Fatal intracranial 
bleeding




Admission for intracranial bleeding in patient treated with 
Nadroparin combined with VKA, INR of 4.0 and concomitant 
uncontrolled hypertension, died the same day, autopsy 
confirmed diagnosis. Hypertension existed at index PE event, 
but was controlled by medication before discharge.
Female 74 Abdominal 
hematoma




One day ICU admission for large hematoma of abdominal 
rectal sheet, INR of 5.3 while still on Nadroparin therapy 
with hypotension, drop in hemoglobin of 2.5 mmol/L, fully 
recovered 
Mortality (n=3*)
Gender Age Adverse event Day Autopsy Brief description
Male 67 Died 29 No Died of metastatic pancreatic cancer, diagnosed before index 
PE
Female 59 Died 59 No Died of metastatic pancreatic cancer, diagnosed before index 
PE
CT = computed tomography; n=number; DVT=deep vein thrombosis; ICU= intensive care unit; IU=international 
units; LMWH=low molecular weight heparin; PE=pulmonary embolism; US=ultrasonography; VKA=vitamin K 
antagonist; VTE=venous thromboembolism
* Including one patient that died of fatal intracranial bleeding, mentioned in section “major bleeding”
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other patients was progressive metastatic pancreatic cancer (at day 29 and 59). The cause of 
death in the two patients with malignancy was clinically adjudicated by the treating physi-
cian. None of the patients died of fatal PE.
Discussion
This study evaluated the efficacy and safety of outpatient treatment of patients presenting 
with acute PE. Patients with acute PE were triaged in a standardized way and eligible patients 
were treated as outpatients. The present study shows that outpatient anticoagulant treat-
ment of patients selected by the exclusion criteria has a low risk for recurrent VTE: VTE re-
curred in 2% of patients, with the upper limit of the CI reaching 4.3%, which is lower than the 
predefined limit of 7%. None of the recurrences was fatal. None of the patients in the present 
study receiving adequate anticoagulant treatment experienced a recurrent VTE event within 
7 days of the initial event, a period which equals the average duration of hospital admission 
for PE.26 
Comparison of the recurrence rate of 2.0% (95% CI 0.8 – 4.3%) found in the present study 
to the VTE recurrence rate of 3.0% (95% CI 1.8-4.6%) in a historical cohort of patients with PE 
treated in the hospital 24 demonstrates almost identical rates, suggesting the efficacy of the 
LMWH treatment at home may be at least as good as the efficacy in the hospital. Moreover, 
our results are similar to outcomes in small prospective studies summarized in a systematic 
review22, a recently performed prospective cohort study8 and results of a large retrospec-
tive cohort13 on outpatient treatment of PE. Of note, our rate is considerably lower than the 
6.2% found in the study of Kovacs et al.12 This discrepancy might be explained by the higher 
proportion of patients with malignancies (25% vs. 9%) in that study. 
The rate of bleeding with the outpatient treatment was low in comparison to bleeding rates 
reported in the literature. In the present study major bleeding occurred in 0.7 % and 5.1% of 
patients had non-major clinically relevant bleeding. In studies with comparable groups of 
patients major bleeding rates in patients with PE treated at home varied between 0% and 
2.8%.22 Moreover, fatal bleeding occurred in only one patient (0.3%) in the present study. This 
is well comparable to the fatal bleeding rates of 0.3%-0.6 % in unselected patients with PE 
treated in the hospital.24,27 
In this study, a simple set of exclusion criteria was used to select patients for outpatient 
treatment. The choice for these criteria was reinforced by former research.12 The criteria 
are pragmatic, easy to use at the bedside, quick to perform and cheap. This study, where 
predefined exclusion criteria were used, 51% of patients with PE could be treated out of the 
hospital, which is comparable to the 51-55% found in two large retrospective studies using 
comparable criteria.11,12 In the literature the use of ‘subjective items’ has been criticized.28 
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However this study shows that physicians guided by the simple bedside criteria are well able 
to distinguish low-risk patients eligible for outpatient treatment. In addition, comparable 
sets of criteria have been used safely in different cohorts from different countries.9,10,12,19-21
Two other approaches have recently been suggested for selecting patients for outpatient 
treatment: the Pulmonary Embolism Severity Index (PESI)29 and NT-proBNP.8 The predictive 
values of PESI and NT-proBNP have been derived from unselected cohorts of patients with 
PE treated in the hospital.30,31 A large cohort study with unselected patients treated for PE in 
the hospital demonstrated that patients with PE and low PESI scores (class I and II) have a risk 
for 90-day mortality of 1.2%.29 A recent meta-analysis showed that unselected patients with 
low NT-proBNP levels have a 30-day mortality of 1.3%.32 The predictive value of the PESI and 
NT-proBNP in patients preselected with pragmatic exclusion criteria is currently unknown. In 
addition, these two selection methods are validated on short-term mortality, but our data 
showed that short-term mortality in preselected groups potentially eligible for outpatient 
treatment is very low (1.0%).    
This study had strengths and limitations that should be addressed. To our knowledge this 
is the largest trial in patients with acute PE who were treated as outpatients within 24 hours 
after the diagnosis of pulmonary embolism. The inclusion of consecutive patients as well as 
the absence of loss to follow-up make that selection bias is no issue in the present study.33
One limitation of the study is that the endpoint ascertainment could not be blinded due 
to the single-arm design of the study. However, ascertainment of both the exposure (PE) 
and the outcome (recurrent VTE) was performed according to predefined criteria, which 
minimizes the risk of information bias. 
The reported recurrence rate of 2% could be an overestimation, because in the five pa-
tients who were centrally judged as having recurrent PE, no objective imaging was done. 
These five patients were centrally adjudicated as recurrent PE because of the clinical signs 
suggestive of recurrent PE and/or the local decision to change anticoagulant therapy. The 
central adjudication committee was conservative on this to avoid an underestimation of the 
recurrence rate. Another limitation is that 23% of patients had to stay in the hospital for up to 
24 hours for logistic reasons. 
Finally, we initially considered a randomized study design with random allocation to inpa-
tient or outpatient treatment, but concluded this was not feasible, owing to the very large 
sample size that would have been needed. Instead, a single-arm clinical trial was performed 
with predefined triaging of patients and careful standardized follow-up in all patients us-
ing predefined criteria for assessing and adjudicating recurrent events and bleeding. Such 
a single-arm trial is a valid instrument to evaluate treatment in a population provided that 
consecutive patients are included and all patients get standardized triaging, to avoid inves-
tigator bias. 
In conclusion, outpatient treatment of acute PE may be effective and safe in patients se-
lected with the predefined and easy-to-use criteria, on the basis of observed low recurrence, 
27
Outpatient treatment of patients with pulmonary embolism: Hestia Study
mortality and bleeding rates. In view of the single-arm trial design, these results have to be 
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We investigated whether the clinical criteria, used in the Hestia study for selection of pulmo-
nary embolism (PE) patients for outpatient treatment, could discriminate PE patients with 
high and low risk for adverse clinical outcome. 
Methods 
We performed a cohort study with PE patients who were triaged with 11 criteria for outpa-
tient treatment. Patients not eligible for outpatient treatment were treated in-hospital. Study 
outcomes were recurrent venous thromboembolism, major bleeding and all-cause mortality 
during 3 months. 
Results 
In total 530 patients were included, of whom 297 were treated at home. In the outpatient 
group six patients (2.0%, confidence interval [CI], 0.7-4.3) had recurrent venous thromboem-
bolism versus nine inpatients (3.9%; CI 1.9-7.0). Three patients (1.0%, CI0.2-2.9) died during 3 
months follow-up in the outpatient group versus 22 patients (9.6%, CI 6.3-14) in the inpatient 
group (p<0.05). In the outpatients none died as a result of fatal pulmonary embolism versus 
five inpatients (2.2%; p<0.05). In outpatients 0.7% (CI 0.08-2.4) had major bleeding events 
versus 4.8% (CI 2.4-8.4) of inpatients (p<0.05).
Conclusion 
This study showed that the Hestia criteria can discriminate PE patients with low risk from 
patients with high risk for adverse clinical outcome. The low risk patients can safely be treated 
at home. (Dutch Trial Register No1319)
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Introduction
Nowadays, most patients with acute pulmonary embolism (PE) start anticoagulant treat-
ment in the hospital, but evidence on the safety of initial outpatient treatment in patients 
with PE is accumulating.1 Two systematic reviews summarized the results of a few small 
observational studies on outpatient treatment in patients with PE.2,3 These reviews con-
cluded that although the evidence is not of high quality, it indicates that certain subgroups 
of patients with PE could be eligible for outpatient treatment. In 2010 two large retrospective 
studies on outpatient treatment of PE patients were published.4,5 In these studies low rates of 
adverse clinical outcome were reported, suggesting safety of outpatient treatment in PE; in 
both articles prospective validation of the results is recommended. 
We have recently published the results of a large prospective study in which clinical signs 
and symptoms were used to select patients with PE for outpatient treatment.6 The Hestia 
criteria consist of 11 clinical criteria that can be used as a bedside test. The purpose of the 
Hestia study was to evaluate the safety of outpatient treatment in patients with acute PE 
triaged by simple and easily performed Hestia criteria. However, in the Hestia Study these 
selection criteria for outpatient treatment were used for the first time. The criteria have not 
been validated in other cohorts yet. In order to underline the discriminative power of the 
Hestia criteria, we wanted to show the contrast between the rates of adverse events in the 
patients treated at home versus the patients treated in the hospital. Therefore, the aim of the 
present extension of the Hestia study was to show the difference in adverse clinical outcome 




The Hestia study was a multicenter prospective cohort study in patients with acute PE who 
were selected for outpatient treatment with the Hestia criteria. The methods of this study are 
described elsewhere.6 
In the Hestia study we prospectively registered all patients that were excluded from out-
patient treatment and the reasons why they were excluded. The excluded patients were not 
study patients because they were not eligible for the intervention of outpatient treatment 
nor were they followed prospectively.  
For the analysis described in this manuscript we retrospectively reviewed the medical 
charts of the patients excluded from home treatment to investigate whether they had a 
recurrent VTE, bleeding or died 3 months following the PE. All suspected outcome events 
Chapter 3
34
were classified by an independent central adjudication committee, whose members were 
not participating in the study. This was the same committee as for the initial Hestia study. The 
Hestia study protocol was approved by the institutional review board of each participating 
hospital.
Patients
Consecutive patients were included according to the following inclusion criteria: >18 years 
with proven acute PE presenting to the Emergency Department. Patients with asymptomatic 
or chronic PE were not included. 
Patients were admitted to the hospital if one of the following exclusion criteria for outpa-
tient treatment (Hestia criteria) were fulfilled: hemodynamic instability, thrombolytic treat-
ment or embolectomy, high bleeding risk, oxygen therapy, intravenous pain medication, 
diagnosis of PE while on therapeutic anticoagulant treatment, medical or social condition 
necessitating hospital admission, renal or liver impairment, pregnancy or history of heparin 
induced thrombocytopenia.
This checklist with 11 items can be used as bedside test and can be completed within 5 
minutes. If none of the items were present the patient was treated at home. All patients were 
treated with standard anticoagulant therapy according to international guidelines.7
Outcome events 
Symptomatic recurrent VTE was the main efficacy parameter and was considered present 
if recurrent PE or DVT were documented objectively, or in case of death in which PE was 
demonstrated by autopsy or could not be confidently ruled out as contributing cause. Major 
bleeding was the main safety outcome and was defined according to international guide-
lines.8 Mortality was defined as death due to recurrent PE (fatal PE), fatal bleeding, cancer, or 
another established diagnosis. Information about the cause of death was obtained from an 
autopsy report or from a clinical report. 
Statistical analysis
The power calculation of the Hestia study is described elsewhere.6 In the initial Hestia study 
we screened patients for eligibility for outpatient treatment until we reached our calculated 
sample size of patients treated at home. The group of PE patients treated in the hospital, 
described in this article, consists of consecutive patients who could not be treated at home. 
These patients were prospectively collected in all 12 hospitals participating in the Hestia 
study from May 2008 till April 2010. 
Differences in baseline characteristics and outcome between the in- and outpatient groups 
were measured with Fisher’s Exact Test for categorical variables and with a T-test for continu-
ous variables. SPSS software version 17.0 (SPSS Inc, Chicago, IL) was used for all analyses.  
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Results
From 2008 to 2010, 581 patients with acute, symptomatic PE presented to 12 Dutch hospitals. 
Of these patients, 338 patients were potentially eligible for outpatient treatment, however 41 
patients were excluded for study reasons (e.g. refusal of participation, previous participation), 
leaving 297 patients for home treatment. In total 243 patients were admitted to the hospital, 
for the following reasons: hemodynamic instability (n=30), thrombolytic treatment for mas-
sive PE (n=5), high bleeding risk (n=14), requirement of oxygen therapy (n=73), severe pain 
requiring intravenous medication (n=15), diagnosis of PE during anticoagulant treatment 
(n=9), medical (n=63) or social (n=24) condition necessitating admission to the hospital. 
In ten patients, the reason for exclusion from outpatient treatment was not specified. Ten 
of 243 patients treated in the hospital had to be excluded from this analysis, because the 
chart review revealed that pulmonary embolism was not objectively proven by imaging. This 
resulted in a total of 530 PE patients: 297 patients treated as outpatients and 233 patients 
treated in the hospital. The baseline characteristics of the outpatient and inpatient groups 
are shown in Table 1. Patients treated in the hospital were significantly older, were more often 
immobilized and had more co-morbidities (cancer, heart failure and chronic obstructive pul-
monary disease (COPD)) than patients treated at home. Four patients were lost to follow-up 
after hospital admission because they lived abroad.
Table 1. Baseline characteristics 
Characteristics Patients treated at home
(n=297)




Age (years) 55 ± 15 62 ± 17 <0.001
Male gender 172 (58) 116 (50) 0.066
Immobilization or surgery 27 (9) 71 (31) <0.001
Paralysis or plaster 10 (3.4) 13 (6) 0.205
Estrogen use 47 (16) 15 (6) 0.001
History of VTE 74 (25) 54 (23) 0.683
Heart failure 1 (0.3) 14 (6) <0.001
COPD 11 (3.7) 24 (10) 0.003
Active malignancy 28 (9) 48 (21) <0.001
Hospitalization (days)* 0.3 ± 0.4 7.4 ± 6.9 <0.001
Categorical data are displayed as No (%). Numerical data are displayed as means ± standard deviation. VTE= 
venous thromboembolism, COPD = chronic obstructive pulmonary disease





In patients treated at home six (2.0%; 0.7-4.3) had recurrent VTE; five patients had non-fatal 
recurrent PE and one patient had recurrent DVT. In patients treated in the hospital nine (3.9%; 
1.9-7.0) had recurrent VTE; all patients had recurrent PE. More than half of all recurrent VTE 
happened in the first 2 weeks after the initial PE (Figure 1). None of the outpatients had fatal 
PE, while five patients (2.2%; 0.8-4.8) treated in the hospital died of fatal PE on day 1, 3, 6, 33 
and 66 (p<0.05; Table 2). All three patients with fatal PE during the first week after the initial 
PE died during hospital admission. None of the fatal recurrences underwent autopsy to prove 
cause of death.
Major bleeding   
Two outpatients had a major bleeding event (0.7%; 0.082-2.4; Table 2) versus 11 inpatients 
(4.8%; 2.4-8.4; p<0.05). The two major bleedings in the outpatients consisted of one fatal 
intracranial bleeding at day 7 and one large abdominal muscle hematoma at day 14. Seven 
(64%) of the major bleedings in the inpatient group happened during the first week of treat-
ment (Figure 2). The locations of the eleven major bleedings in the inpatient group were: 
intracranial hemorrhage (fatal), two intra-abdominal bleedings, gastrointestinal bleeding, 
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pericardial bleeding, bleeding in a pacemaker pocket, hemarthros, hematuria, large subcu-
taneous hematoma of arm and breast, intravenous catheter related bleeding and a muscle 
hematoma of the upper leg. Five of eleven (45%) major bleedings in the inpatient group 
happened during thrombolytic treatment, but none of these were fatal.  
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Table 2. Adverse clinical outcome in 3 months follow-up period 
Clinical outcome All PE patients 
(n=526)*
PE patients treated as 
outpatients (n=297)





































All-cause mortality 25 (4.8) 3 (1.0) 22 (9.6) <0.001
Data are displayed as No (%). 
PE = pulmonary embolism, DVT = deep vein thrombosis, NS=non-significant




During 3 months follow-up 25 patients (4.8%; 2.6-8.2) died. Seven patients (28%) died of 
causes related to PE or bleeding, as described above. Other causes of death were mostly 
malignancies (9; 36%), respiratory insufficiency (5; 20%) or myocardial infarction (2; 8%). In 
the patients treated at home three patients (1.0%; 0.21-2.9) died versus 22 patients (9.6%; 6.3-
14) treated in the hospital (p<0.05; Table 2). None of the patients treated at home died within 
the first week versus four patients treated in the hospital (p<0.05). Three of these inpatients 
died of fatal progression of PE and one inpatient had a fatal bleeding. Active malignancy 
was present in 16 patients (64%) when they died. When patients with malignancies were 
excluded, 3-month mortality was 0.4% (95% CI 0.009-2.1) in the outpatients and 4.4% (95% 
CI 1.9-8.5) in the inpatients.
Discussion
Our study demonstrates that when patients were selected for out- or inpatient treatment 
with the Hestia criteria, outpatients had less clinical adverse events than patients treated 
in the hospital. None of the outpatients died of fatal PE, versus five of the inpatients and 
inpatients also had a higher overall mortality within the first week; this period equals the 
average duration of hospital admission.9 From this we can conclude that the Hestia criteria 
discriminate well between PE patients at high and low risk for adverse events and adequately 
select low risk patients for outpatient treatment. 
In 2010 two retrospective studies on outpatient treatment of PE have been published.4,5 
The Hestia Study is an important prospective validation of these retrospective studies. Our 
results provide a firm validation and an extension of the results of the retrospective studies 
regarding the safety of outpatient treatment.  In both the study presented here and the study 
of Erkens et al the rate of fatal PE was 0% in the outpatient and 2% in the inpatient group.4 
Overall recurrent VTE rates, major bleeding rates and mortality are higher in the retrospective 
study than in the Hestia Study, although not statistically, because the confidence intervals 
overlap. In the Hestia study we found recurrent VTE rates of 2.0% in the outpatients and 3.9% 
in the inpatients versus 3.8% in outpatients and 4.7% in inpatients in the retrospective study. 
Major bleeding rates were 0.7% in outpatients and 4.8% in inpatients in the Hestia Study and 
1.5% and 6.1% in the other study. In the study of Erkens et al mortality was 5% in outpatients 
and 26% in inpatients, which is higher than in the 1.0% and 9.6% in the Hestia Study. The 
explanation for the higher rates of adverse outcome in the retrospective study could be that 
their study population contained a higher proportion of patients with malignancies com-
pared to the Hestia population (36% versus 14%). The proportion of malignancies of 14% we 
found in the Hestia Study is more comparable to proportions of malignancies observed in 
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other large studies on anticoagulant treatment in patients with PE.10,11 In our view this adds to 
the generalisability of our results.  
The other retrospective study by Kovacs et al did not give clinical outcomes of patients 
treated in the hospital.5 The rates of adverse clinical outcome in the outpatient group are 
comparable to the rates in the Hestia Study: in the patients treated at home none died of 
fatal PE.  
Recently the first randomized controlled trial on outpatient treatment in patients with PE 
was published.12 They concluded that outpatient treatment was non-inferior to inpatient 
treatment regarding recurrent VTE and mortality, but the major bleeding rate was a little 
higher in the outpatient group. The recurrent VTE and mortality rates in the outpatient group 
of the randomized trial were lower than the rates in the Hestia study, but this could be due to 
a highly selected population of young and healthy PE patients: mortality 0.6% and recurrent 
VTE 0.6%. Despite the selection of young patients with a low proportion of co-morbidities the 
major bleeding rate of 1.8% was higher than in our study, although the confidence intervals 
overlap. 
The strength of the Hestia Study is that, it is the largest study on outpatient treatment, 
but there are some limitations to our study: because we did chart review and no prospective 
study follow-up of the inpatients, some events could have been missed. Because almost all 
patients had a complete follow-up, it is not likely that we missed important events like fatal 
PE or fatal bleeding. Within the setting of the Hestia study, PE patients who were treated at 
home were closely followed. Before outpatient treatment can become a standard of care, it is 
essential that close follow-up of PE patients treated at home can be guaranteed in every day 
patient care, especially during the first week.  
Another limitation is that one patient in the home treatment group died of fatal intracra-
nial bleeding. The exclusion of patients with high bleeding with the Hestia criteria led to a 
significantly lower bleeding rate in patients treated at home versus patients treated in the 
hospital (0.7% vs. 4.8%; p=0.003). Despite this careful triaging procedure, one patient in the 
home treatment group died of major bleeding. That patient had poorly controlled hyperten-
sion as an additional risk factor for bleeding in retrospect. Therefore physicians should be 
very careful in selecting patients for outpatient treatment, especially those with risk factors 
for major bleeding.  
In the study presented here, the Hestia criteria have been used to select patients with PE 
for outpatient or inpatient treatment. Comparable criteria have been used in other studies 
abroad, but Dutch doctors used these criteria for the first time. In the Hestia Study the criteria 
were used by doctors with different specialties and levels of experience. Taken together with 
the favorable findings, this reinforces the feasibility of these criteria to be used by all kinds of 
specialists without restriction to thrombosis experts. However, because it was the first time 
the Hestia criteria were used these results have to be confirmed in future studies.
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In conclusion, evidence on the safety of outpatient treatment in low risk patients with PE 
is accumulating. The Hestia criteria can be used to discriminate PE patients with low risk for 
adverse clinical outcome from patients with high risk for adverse clinical outcome. The low 
risk patients can be safely treated at home.
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The aim was to study the safety of outpatient treatment in low risk patients with acute pul-
monary embolism (PE) compared to inpatient treatment, the current clinical standard.
Methods and results 
We searched Medline, Web of Science, Cochrane and EMBASE databases and included co-
hort studies or randomized controlled trials on outpatient treatment of PE. The outcomes 
were recurrent venous thromboembolism (VTE), major bleeding and all cause mortality in 
a 3 months follow-up period. We identified thirteen studies with a total of 1657 PE patients 
treated as outpatients (discharge <24 hours), two studies including 184 patients discharged 
within 72 hours (early discharge) and five studies totaling 455 patients treated as inpatients. 
The pooled incidence of recurrent VTE was 1.7% (95% confidence interval 0.92-3.1) in out-
patients, 0.48% (95% CI 0.02-11) in patients discharged early and 1.2% (95%CI 0.20-7.9) in 
inpatients. The pooled incidence of major bleeding was 1.0% (95% CI 0.58-1.6) in outpatients, 
0.48% (95% CI 0.02-11) in early discharge patients and 1.1% (95% CI 0.46-2.6) in inpatients. 
The pooled incidence of mortality was 1.9% (0.79-4.6) in outpatients, 1.6% (0.53-4.9) in early 
discharge patients and 0.80% (0.06-9.9) in inpatients. The outpatient mortality risk decreased 
to 0.60% (0.22-1.6) after excluding studies that exclusively included patients with malignan-
cies.
Conclusion 
Incidences of recurrent VTE, major bleeding and, after correction for malignancies, mortality 
were comparable between outpatients, patients discharged early and those after full inpa-
tient treatment. We conclude that home treatment or early discharge of selected low-risk 
patients with acute PE is as safe as inpatient treatment.í
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Introduction
Traditionally patients with pulmonary embolism (PE) are initially treated with anticoagulants 
in a hospital setting, with a mean length of hospital stay of 6 days.1 The outpatient treatment 
of patients with deep vein thrombosis (DVT) is internationally accepted and graded with a 
1B recommendation by the American College of Chest Physicians (ACCP).2 Because of limited 
evidence, the international guidelines give only a grade 2B recommendation regarding the 
early discharge of PE patients.2,3 Notably, in recent years several large studies were published 
on this matter, including the first completed randomized controlled trial.4-7 Results from 
those studies suggest that outpatient treatment is as safe as standard inpatient treatment.
Patients with PE treated in the hospital have a low risk of 0.4% for fatal recurrent PE within 
the first 3 months and a 3% risk for non-fatal recurrent PE.8 Fatal major bleeding occurs in 
0.2% of patients within 3 months after PE, with a non-fatal major bleeding rate of 2.0%.8,9 
Before outpatient treatment in low risk PE patients can be accepted as standard patient care, 
comparable safety to inpatient care has to be proven.10 Two systematic reviews concern-
ing outpatient treatment in patients with acute PE have been published.11,12 These reviews 
demonstrated low incidences of recurrent venous thromboembolism (VTE), major bleeding 
and mortality, but the quality of the included small observational studies was low. The most 
recent and largest studies, including one randomized controlled trial, were not included in 
these reviews.4-7
This meta-analysis compared the risk for adverse outcome in specific low risk patients who 
were selected for outpatient treatment (discharge within 24 hours), to the risk for adverse 
outcome in patients with a comparable risk profile, who were discharged early (discharge 
within 72 hours) and to the risk in patients treated in the hospital. This second category is 
relevant in hospitals in which discharge within 24 hours is not possible due to logistical 
reasons. Our aim was to evaluate whether outpatient treatment and early discharge are as 
safe as traditional inpatient treatment in patients with PE.
Methods 
Data sources and searches
We performed a systematic literature search in Medline, Web of Science, Cochrane and EM-
BASE to identify all studies on clinical outcome of PE patients treated at home or discharged 
early. The search was performed using predefined search terms: “pulmonary embolism” or 
“pulmonary thromboembolism” and “home treatment” or “outpatient treatment” or “ambu-
lant treatment” or “early discharge”. The search was developed and conducted by the authors 
in conjunction with a librarian with experience in meta-analyses. The search was restricted to 
English, French, German or Dutch articles. The last search was performed on July 5th 2011. 
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There were no restrictions on publication date or status. We also hand-searched the reference 
lists of the two previous systematic reviews.11,12 
Study selection
Two investigators (W.Z. and J.K.) independently performed the study selection. A third inves-
tigator was consulted in case of disagreement (F.A.K.). 
Only randomized controlled trials or cohort studies which included patients with acute, 
symptomatic, objectively proven PE were selected. To be eligible, at least a part of the study 
population had to be treated with anticoagulants at home or had to be discharged early. 
We did not include studies in which the definition for home treatment or early discharge 
allowed for a hospital admission of more than 3 days. Also, studies which did not explicitly 
mention the outpatient setting of the anticoagulant treatment were excluded. If relevant, 
outcome data had to be reported for in- and outpatients separately. In studies including both 
patients with DVT (without PE) and PE, outcome parameters had to be reported for DVT and 
PE patients separately.
To allow for a fair comparison, this meta-analysis was limited to studies with low risk PE 
patients, i.e. who had a clinical condition which made outpatient treatment possible. Because 
only low-risk patients were selected in all studies that reported on outpatient treatment or 
early discharge, patients could only be included in the inpatient cohort of our analysis if they 
had been selected on the basis of identical prognostic criteria. Hence, studies investigating 
only high risk PE patients (patients who could not be treated at home due to medical condi-
tions) or mixed high and low risk patients were excluded from the present meta-analysis.
Study outcomes
The main outcomes of this study were the pooled incidences of recurrent VTE, major bleeding 
and all-cause mortality during 3 months in patients with PE treated at home versus patients 
discharged early and patients treated as inpatients. Symptomatic recurrent VTE was the main 
outcome. Recurrent VTE was considered present if recurrent PE or DVT were documented 
objectively, or in case of death in which PE could not be confidently ruled out as a contribut-
ing cause. The objective criterion for the diagnosis of recurrent PE was a new filling defect 
revealed by pulmonary angiography or computed tomography pulmonary angiography 
(CTPA) or a new high probability perfusion defect revealed by ventilation-perfusion(V/Q) 
scan or any new defects after earlier normalizing of the scan. The objective criterion of a new 
DVT was a new venous segment of the thrombus on ultrasonography or a new intraluminal 
filling defect on contrast venography. 
Major bleeding was defined as fatal bleeding, and/or symptomatic bleeding in a critical 
area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, 
pericardial or intramuscular with compartment syndrome, and/or bleeding causing a fall in 
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hemoglobin level of more than 2.0 g/dL (1.3 mmol/L), or leading to transfusion of more than 
two units of whole blood or red cells.13
Data extraction and risk of bias assessment
We developed a data extraction sheet containing items on risk of bias, patient characteristics 
(age, sex, co-morbidities), study characteristics, in- and exclusion criteria for outpatient 
treatment, definition of home treatment or early discharge, length of follow-up, outcome 
measures and anticoagulant treatment. The data extraction sheet was completed for all 
eligible studies by two independent authors (W.Z., J.K.).   
The Cochrane collaboration tool for bias risk assessment was used in order to asses the 
risk of bias in the individual studies.14 We adapted the Cochrane collaboration tool for the 
use in cohort studies. The following design items were included for risk of bias assessment: 
adequacy of exposure assessment, clear selection for outpatient treatment, consecutive 
patients, adequacy of follow-up and adequacy of outcome assessment. Assessment of expo-
sure was considered adequate when the index PE was diagnosed with one of the following 
imaging techniques: pulmonary angiography, CTPA, high probability V/Q scan or intermedi-
ate probability V/Q scan combined with a positive compression ultrasonography for DVT. 
An unambiguous selection for outpatient treatment was present if predefined criteria were 
used to select whether or not a patient could be treated as an outpatient. A study popula-
tion was considered adequate if it consisted of consecutive patients or included a random 
sample of all potentially eligible patients. Complete follow-up in at least 80% of patients was 
considered adequate. Assessment of outcome was adequate when objective criteria were 
used, comparable to the international criteria for assessing recurrent VTE or major bleed-
ing.13,15 Recurrent VTE had to be objectively diagnosed by CTPA, V/Q scanning or pulmonary 
angiography. Major bleeding had to be defined by the International Society of Thrombosis 
and Haemostasis (ISTH) criteria or comparable criteria. 
Data synthesis and analysis
Meta-analysis was performed using an exact likelihood approach. The method used was a 
logistic regression with a random effect at the study level.16 Given the expected clinical het-
erogeneity, a random effects model was performed by default, and no fixed effects analyses 
were performed. For meta-analysis of proportions, the exact likelihood approach based on a 
binomial distribution has advantages compared with a standard random effects model that 
is based on a normal distribution.17 First, estimates from a binomial model are less biased 
than estimates from models based on a normal approximation.18 This is especially the case for 
proportions that are close to 0 or 1. Secondly, no assumptions are needed for the exact ap-
proximation when dealing with zero-cells, whereas the standard approach needs to add an 
arbitrary value (often 0.5) when dealing with zero-cells. Adding values to zero-cells is known 
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to contribute to the biased estimate of the model.19,20 Meta-regression analyses were also 
performed with an exact likelihood approach.
A pre-specified subgroup analysis of studies with low proportions of malignancies (<15%) 
was performed, because malignancy is a known risk factor for recurrent VTE, mortality and 
bleeding.21,22  The outcomes according to the intention-to-treat principle were used in the 
meta-analysis. Confidence intervals (CI) of 95% around the reported incidences of recurrent 
VTE, major bleeding and all cause mortality in the individual studies were calculated with the 
Fishers Exact Test. All analyses were performed with STATA 12.0 (Stata Corp., College Station, 
TX).
Results
Study selection and characteristics
The literature search identified a total number of 1576 studies; 1532 were excluded after 
reviewing the title and abstract and another 29 were excluded after reading the full article. 
The reasons for exclusion of studies are listed in Figure 1. The reviewing process resulted in 
15 studies eligible for inclusion in the review.4-7,23-33 
1576 identified studies
44 potentially relevant 
studies
1532 excluded after review of title and 
abstract
1477 after reading title
55 after reading abstract
29 excluded after reading fulltext:
8 excluded because no home 
treatment (or early discharge)
10 excluded because of no results 
for PE patients reported separately
10 excluded because duplicate 
studies
1 excluded because full text only in 
slovenian
15 studies included
Figure 1: Flow chart: selection of studies
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All were published in the English language. All but two studies reported outcome measures 
at 3 months; one study reported outcomes at 6 months 32 and one study reported outcomes 
at the end of the acute phase (mean 6 days).27 All but one studies reported on the 3 outcome 
measures: recurrent VTE, major bleeding and all cause mortality.28 Four studies reported 
both inpatient and outpatient groups4,24,29,31 of which one study randomized the patients for 
in- or outpatient treatment.4 Another study reported early discharge and outpatient groups 
separately.26 Finally, one study reported an early discharge group only 25 and eight studies 
reported an outpatient group only.5-7,23,27,28,32,33 
The included studies involved 2296 patients: 1657 were treated as outpatients, 184 were 
discharged early and 455 were selected low risk patients treated as inpatients. 
Risk of bias assessment
Of 15 included studies, three were randomized controlled trials, twelve were cohort studies; 
eight with prospective patient inclusion and four with retrospective patient selection. Only 
two randomized controlled trials randomized patients between home treatment or early 
discharge and hospital treatment,4,30 of which one was stopped early;30 the trial by Wells 
et al. did not randomize between in- and outpatient treatment, but compared two LMWH 
regimens.33 A proportion of the PE patients in both LMWH randomization groups was treated 
at home. The trial performed by Aujesky et al. was well designed with a full score on the risk 
of bias assessment (Table 1). The main limitation of the trial by Otero et al. is that there could 
be a limited generalizibility of the results, because 30% of patients with PE were not included 
in the study for reasons unclear.
In the low risk outpatients group, five studies,4,5,7,23,33 which contributed 59% of the pa-
tients, had a maximum score on the risk of bias assessment. These studies represented also 
the highest proportions of outcomes; therefore it is not likely that possible selection bias in 
the smaller studies largely affects the magnitude of the outcomes.   
The outcomes in the early discharge group are mainly based on the study by Davies et 
al.25 The main limitation of this study is that there could be an underestimation of the risk of 
adverse outcome due to selection of low risk patients. 
The outcomes in the inpatient group were based for 66% on the inpatient groups of the 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2: Criteria for exclusion of patients for outpatient treatment
Exclusion criterion Which studies? Definition
1. Extra tools for risk stratification Agterof NT-proBNP>500 ng/mL
Aujesky Pulmonary Embolism Severity Index>85*
Lui Massive pulmonary embolism
Olsson Large PE (affecting >40% longperfusion on  V/Qscan)
Otero Clinical score >2, Troponin T>0.1 ng/mL, RV dysfuction 
on TTE
Rodriguez Massive PE (two or more lobar branches)
2. Hemodynamically unstable Agterof, Aujesky, Beer, Erkens, Kovacs 2000, Kovacs 2010, Lui, Ong, Otero, Rodriguez, Wells, 
Zondag
3. Respiratory unstability Agterof, Aujesky, Davies, Erkens, Kovacs 2000, Kovacs 2010, Lui, Ong, Otero, Rodriguex, 
Wells, Zondag
4. Intravenous pain medication Agterof, Aujesky, Davies, Kovacs 2000, Kovacs 2010, Olsson, Ong, Siragusa, Wells, Zondag
5. Bleeding risk Agterof, Aujesky, Beer, Davies, Erkens, Kovacs 2000, Kovacs 2010, Lui, Olsson, Ong, Otero, 
Rodriguez, Siragusa, Wells, Zondag 
6. Therapeutic anticoagulation at 
time of diagnosis PE
Aujesky, Beer, Davies, Wells, Zondag
7. Co-morbid conditions requiring 
hospital admission
Agterof, Davies, Erkens, Kovacs 2000, Olsson, Ong, Otero, Rodriguez, Siragusa, Wells, 
Zondag
8. Social conditions Agterof, Aujesky, Beer, Davies, Kovacs 2000, Lui, Ong, Rodriguex, Siragusa, Wells, Zondag
9. Pregnancy Agterof, Aujesky, Davies, Otero, Zondag
10. Renal insufficiency Agterof, Aujesky, Beer, Erkens, Rodriguez, Siragusa, Wells, Zondag
11. Contraindication to heparins Aujesky, Beer, Lui, Rodriguez, Wells, Zondag
12. Concomitant deep vein 
thrombosis
Davies, Wells
13. Obesity Aujesky, Beer, Otero
14. Liver impairment Zondag
PE= pulmonary embolism; RV=right ventricular; TTE = transthoracic echocardiography
*Aujesky et al. Am J Respir Crit Care Med 2005;172(8):1041-1046
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Selection of low risk patients for outpatient treatment or early discharge
Different methods of defining PE patients as low risk for adverse events were used (Table 2). 
Most studies used comparable clinical criteria5-7,25-27,29,31-33 to select patients for outpatient 
treatment. In Table 2, the clinical criteria for selecting patients for outpatient treatment used 
in the different studies are summarized. More than 10 studies used at least the following 
criteria for exclusion of patients from outpatient treatment: hemodynamic instability (mostly 
defined as systolic blood pressure < 100 mmHg), respiratory instability (mostly defined as 
hypoxia on breathing room air), severe pain and need for parenteral narcotics, high bleeding 
risk and co-existing co-morbid diseases or social problems requiring hospital admission. 
Other important factors to consider when patients are screened for outpatient treatment are: 
whether they have altered pharmacokinetics due to pregnancy or renal/liver insufficiency or 
contra indications for heparins like allergies or previous heparin induced thrombocytopenia. 
Some studies used an additional clinical decision rule,4,24,30 a laboratory test 23 or imaging 
test (Table 2).28 The demographic characteristics age and sex were comparable among the 
studies: mean age ranged between 47 and 67 years and 30-58% of patients were male (Table 
1). Notably, the proportion of malignancies varied widely among the studies: from 1-100%. In 
one study solely PE patients with malignancies were investigated.32
Outpatient anticoagulant treatment
In most of the studies, outpatient treatment was defined as hospital discharge within 24 
hours. In the two studies reporting an early discharge group the mean duration of hospital 
admission was 1.0 days 25 and 2.5 days.26 The study of Otero et al. reported on two groups: 
the first group of patients was discharged after a mean of 3.4 days and the second group was 
discharged after a mean of 9.3 days.30 Because the two groups had a mean duration of hospi-
tal admission over 72 hours, both were analyzed in the inpatient cohort of the meta-analysis. 
In all fifteen studies patients were treated with a combination of LMWH and vitamin K 
antagonists, except for patients with an indication for LMWH treatment alone, for example 
patients with malignancies. Most of the studies reported a minimum of 5 days of LMWH treat-
ment, until the INR was in the therapeutic range of 2.0-3.0. Nadroparin once daily was used in 
two studies,7,24 tinzaparin once daily in two studies,25,28 daltaparin once daily in one study,26 
four studies used more than one LMWH protocol and in five studies the type of LMWH used 
was not specified. In summary, nine studies used once daily LMWH5,7,23-26,28,33 and one study 
used twice daily LMWH.4 The other studies used more than one LMWH protocols or it was not 
described. In at least six studies a part of the patients injected LMWH themselves after instruc-
tion of a nurse.4,7,23,26,29,32 Warfarin was used in seven studies6,25-28,32,33 and other forms of VKA 
treatment (phenprocoumon, acenocoumarol, fluidione) were used in five studies.7,23,24,30,31 In 
three studies the type of VKA was not specified or more than one protocol was used.4,5,29 In 




In 13 studies a total of 1657 PE patients were treated as outpatients and 33 patients had a 
recurrent VTE (Table 3). None of these recurrent events were fatal. The pooled VTE recurrence 
risk of patients treated as outpatients was 1.7% (95% CI 0.92-3.1). In two studies, a total of 
184 patients were discharged early, in which one patient had a non-fatal recurrent VTE. The 
pooled VTE recurrence risk of patients discharged early was 0.48% (95% CI 0.02-11). In the five 
studies describing 455 PE patients treated as inpatients, 10 patients had recurrent VTE. The 
pooled VTE recurrence risk of patient treated as inpatients was 1.2% (95% CI 0.20-7.9; Figure 
2). After excluding studies with a high proportion of patients with malignancies as previously 
stated, the pooled incidence of recurrent VTE did not change significantly (p=0.053).
Table 3. Outcome during 3 months after pulmonary embolism




Agterof 23 152 0 0.0-2.4 0 0.0-2.4 0 0.0-2.4
Aujesky 4 171 1 (0.6) 0.01-3.2 1 (0.6) 0.01-3.2 3 (1.8) 0.4-4.7
Beer 24 43 1 (2.3) 0.06-12.3 0 0.0-6.7 0 0.0-6.7
Erkens 5 260 10 (3.8) 1.9-7.0 13 (5) 2.7-8.4 4 (1.5) 0.4-3.9
Kovacs 26 81 5 (6.2) 2.0-13.8 4 (4.9) 1.4-12.2 1 (1.2) 0.03-6.7
Kovacs 6 314 3 (0.95) 0.2-2.8 9 (2.9) 1.3-5.4 3 (0.95) 0.2-2.8
Lui27* 21 0 0.0-16.1 0 0.0-16.1 0 0.0-16.1
Olsson 28 102 0 0.0-3.6 4 (3.9) 1.1-9.7 - -
Ong 29 60 3 (5.0) 1.0-13.9 1 (1.7) 0.04-8.9 1 (1.7) 0.04-8.9
Rodriguez-
Cerrillo 31
30 0 0.0-11.6 0 0.0-11.6 0 0.0-11.6
Siragusa 32† 36 2 (5.5)  0.7-18.7 11 (30.5) 16.4-48.1 1 (2.7) 0.07-14.5
Wells 33 90 2 (2.2) 0.3-7.8 3 (3.3) 0.7-9.4 0 0.0-4.0
Zondag 7 297 6 (2.0) 0.8-4.3 3 (1.0) 0.2-2.9 2 (0.67) 0.008-1.9
Early discharge
Davies 25 157 0 0.0-2.3 3 (1.9) 0.4-5.5 0 0.0-2.3
Kovacs 26 27 1 (3.7) 0.09-19.0 0 0.0-12.8 1 (3.7) 0.09-19.0
Inpatients
Aujesky 4 168 0 0.0-1.8 0 0.0-1.8 1 (0.6) 0.01-3.3
Beer 24 54 2/65 (3.1)‡ 0.4-10.7 0 0-5.5 0 0-5.5
Ong 29 70 4 (5.7) 1.6-14.0 3 (4.3) 0.9-12.0 2 (2.9) 0.3-9.9
Otero 30 132 4 (3.0) 0.8-7.6 8 (6.1) 3.1-11.5 2 (1.5) 0.2-5.4
Rodriguez-
Cerrillo 31
31 0 0.0-11.2 0 0.0-11.2 0 0.0-11.2
CI= confidence interval; VTE=venous thromboembolism; Categorical data are displayed as number (percentage); 
continuous data are displayed as mean (standard deviation).
*mean duration of follow-up 6 days (range 3-11), no long term outcome available; †outcome measured at 6 
months after diagnosis of pulmonary embolism; 
‡2 recurrent PE in total inpatient group (N=65), not specified for high (N=11) or low risk (N=54) group.
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Meta-analysis: major bleeding 
In the 1657 PE patients that were treated as outpatients, 15 patients had a major bleeding of 
which three proved fatal (Table 3). The pooled major bleeding incidence of patients treated 
as outpatients was 0.97% (95% CI 0.58-1.6). In 184 patients who were discharged early, one 
patient had a fatal major bleeding. The pooled major bleeding risk of patients discharged 
early was 0.48% (95% CI 0.02-11). In 455 PE patients who were treated as inpatients, five 
patients had major bleeding of which one was fatal. The pooled major bleeding risk of 
patients treated as inpatients was 1.1% (95% CI 0.46-2.6). The pooled incidences did not 
differ significantly between the groups (Figure 2). The pooled incidence of major bleeding 
did not change significantly after excluding studies with a high proportion of patients with 
malignancies (p=0.44). 
Meta-analysis: all-cause mortality
In the total of 1657 PE patients that were treated as outpatients 49 patients died (Table 3). 
None of the patients died of fatal PE. The pooled mortality risk of patients treated as outpa-
tients was 1.9% (95% CI 0.79-4.6). In the 184 patients discharged early, three patients died. 
The pooled mortality risk of patients discharged early was 1.6% (95% CI 0.53-4.9). In 455 PE 
patients treated as inpatients, 11 patients died. The pooled mortality risk of patient treated 
as inpatients was 0.80% (95% CI 0.06-9.9). The pooled incidences did not differ significantly 
between the groups (Figure 2). After excluding studies with a maximum of 15% of patients 
with malignancies, the pooled incidence of mortality in outpatients decreased to 0.60% (95% 
CI 0.22-1.6). This was significantly different from the pooled incidence of mortality of 4.2% 
Recurrence Home treatment           13 1.70 (0.92, 3.12)
Recurrence Early discharge               2 0.48 (0.02, 11.20)
Recurrence Hospital treatment        4 1.24 (0.20, 7.87)
Mortality Home treatment           13 1.94 (0.79, 4.64)
Mortality Early discharge               2 1.63 (0.53, 4.93)
Mortality Hospital treatment        5 0.80 (0.06, 9.89)
Bleeding Home treatment           12 0.97 (0.58, 1.59)
Bleeding Early discharge               2 0.48 (0.02, 11.19)
Bleeding Hospital treatment        5 1.10 (0.46, 2.61)         
Outcome Cohort Studies Absolute risk (95% CI)
0                    5                    10                  15      (%)
Figure 2: Pooled incidences of clinical outcome after pulmonary embolism in patients treated at home, 
discharged early or treated as inpatients
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(95% CI 2.0-8.6) in the outpatient studies with a high proportion (>15%) of malignancies 
(p=0.003). 
Discussion
The results of the present meta-analysis indicate that the pooled incidences of recurrent 
VTE and major bleeding in selected patients with PE treated at home or discharged early 
within 3 days are equivalent to those incidences of comparable selected patients with PE 
treated in the hospital. 
While the point estimates of mortality were higher in the outpatient than in the inpatient 
group (1.9% vs. 0.80%), the confidence intervals are overlapping. Importantly, no fatal PE oc-
curred in the patients treated at home or discharged early. When outpatients were compared 
to early discharge or inpatients with comparable malignancy rates (<15%), the incidences of 
mortality were equal in outpatients and inpatients (0.60% vs. 0.80%). 
Most of the studies excluded patients with a high risk for major bleeding. This resulted in 
low pooled incidences of major bleeding in outpatients, early discharge patients and inpa-
tients of 0.5-1.1%. However, the case-fatality rate of major bleeding is high: 20% (95% CI 4-48) 
in outpatients and a comparable 20% (95% CI 0.5-72) in patients treated in the hospital. The 
comparable incidences of major bleeding in outpatients (1.0%) versus inpatients (1.1%) and 
the comparable case-fatality rates in both groups indicate that treating patients at home may 
not enhance unfavorable outcome of bleeding events and therefore underlines the safety of 
outpatient treatment.
Outpatient treatment and early discharge of patients with PE should be restricted to pa-
tients with low risk for adverse clinical outcome. In the included studies, different methods 
for selection of low risk patients were used. All studies used a list of pragmatic exclusion 
criteria for outpatient treatment (Table 1) which mostly contained items on hemodynamic or 
respiratory compromise, high bleeding risk, co-morbidity and predicted therapy compliance. 
In addition some studies used a formal, validated method to select patients at low risk for ad-
verse clinical outcome. The only completed randomized controlled trial used the Pulmonary 
Embolism Severity Index (PESI), a clinical prognostic score based on signs and symptoms.4 
Patients in the low risk PESI classes have a risk for 90-day all-cause mortality of 1% or lower.34 
Other studies used different clinical risk scores,24,30,35 the laboratory value NT-proBNP,23 or 
imaging parameters like the size of the embolus 27,31 or the size of the perfusion defect.28 The 
proportions of patients that could be selected for outpatient treatment varied among the 
studies from 30% to 55%, depending on the extensiveness of the selection method.     
The strength of this study is that it is the first meta-analysis on outpatient treatment in 
PE patients with pooled incidences of adverse clinical outcome. Another strength is that 
this meta-analysis discriminates between patients treated entirely at home (<24 hours) 
and patients discharged early (24-72 hours). Furthermore, a highly relevant control group 
of low risk patients treated in the hospital was added for the comparison with outpatient 
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and early discharge groups. The selected control group of low risk inpatients, i.e. PE patients 
with clinical conditions which make them potentially eligible for outpatient treatment, is 
relevant because it enhances comparability of baseline risk factors for adverse outcome, like 
co-morbidity and severity of pulmonary embolism, between the groups.
This meta-analysis also has some limitations. Although the results presented here indicate 
that outpatient treatment and early discharge may be as safe as treatment in the hospital, 
the level of evidence of the included studies remains limited. Until now, only one randomized 
controlled trial on outpatient treatment of PE patients has been completed.4 The trial by Otero 
et al. was stopped early because of two deaths within 14 days in the early discharge group 
versus none in the standard hospitalization group, which was too high for their predefined 
margins, but this proportion had wide confidence intervals and was not statistical significant. 
The lack of more high quality randomized controlled trials means that our conclusions can 
not be supported by grade 1A evidence yet. However, well designed cohort studies can also 
provide reliable evidence. This meta-analysis included five high quality observational stud-
ies with many patients and no serious sources of bias (Table 2). Therefore we conclude that 
the estimates of incidences of adverse outcome are reliable. Another drawback is that one 
of three treatment groups was small: only two studies described patients discharged early. 
Therefore the confidence intervals of the incidences in this group were wide. On the other 
hand, the incidences of recurrence, bleeding and mortality in the outpatients groups are 
representative, because they were based on 1657 patients form 13 studies. Third, the autopsy 
rates in all studies were low giving some uncertainty about whether PE related mortality was 
really absent. Fourth, before outpatient treatment can be implemented in clinical care, close 
follow-up of patients, especially in the first weeks, must be guaranteed. This could implicate 
that outpatient treatment of patients with PE will be reserved for countries with a solid net-
work of thrombosis clinics.
In conclusion, the results of the present meta-analysis demonstrate the safety of outpatient 
treatment and early discharge in selected low risk patients with pulmonary embolism. This 
conclusion is also supported by the latest ACCP guideline with a grade 2B recommendation.2 
More randomized controlled trials on outpatient treatment of pulmonary embolism patients 
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The aim of this study is to compare the performance of two clinical decision rules to select 
patients with acute pulmonary embolism (PE) for outpatient treatment: the Hestia criteria 
and the simplified Pulmonary Embolism Severity Index (sPESI). 
Methods
 From 2008 to 2010, 468 patients with PE were triaged with the Hestia criteria for outpatient 
treatment: 247 PE patients were treated at home and 221 were treated as inpatients. The 
outcome of interest was all-cause 30-day mortality. In a post-hoc fashion, the sPESI items 
were scored and patients were classified according to the sPESI in low and high risk groups. 
Results 
Of the 247 patients treated at home, 189 (77%) patients were classified as low risk accord-
ing to the sPESI and 58 patients (23%) as high risk. In total, 11 patients died during the first 
month; two patients treated at home and nine patients treated in-hospital. None of the 
patients treated at home died of fatal PE. Both the Hestia criteria and sPESI selected >50% of 
patients as low risk, with good sensitivity and negative predictive values for 30-day mortality: 
82% and 99% for the Hestia criteria and 91% and 100% for the sPESI, respectively.     
Conclusions 
The Hestia criteria and the sPESI perform equally well in predicting short-term mortality in 
patients with acute PE. However, this study demonstrates that the Hestia criteria are able to 
identify a significant proportion of patients classified as high risk by sPESI who can be safely 
treated at home.
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Introduction
Evidence on the safety of outpatient treatment or early discharge of selected low-risk patients 
with acute pulmonary embolism (PE) is accumulating. The recent American College of Chest 
Physicians guidelines give a grade 2B recommendation on the safety of early discharge of 
selected PE patients and the European Society of Cardiology guidelines suggest that low risk 
PE patients, with negative markers for right ventricular dysfunction or myocardial ischemia, 
could be treated at home.1,2  
When considering outpatient treatment for patients with acute PE, the crucial step is 
to select those patients who are at low risk of adverse outcome. For this purpose, several 
methods to aid in the selection of low risk patients have been investigated: clinical signs and 
symptoms,3,4 laboratory values5 or imaging techniques.6 The most widely validated method 
for selection of low-risk patients with PE, is the Pulmonary Embolism Severity Index (PESI)7,8; 
a clinical decision rule, containing 11 items based on signs and symptoms of the patient. 
The PESI has been prospectively tested in a randomized controlled trial,9 in which low risk 
patients, with <85 points on the PESI, were randomized between home or hospital treat-
ment. Patients treated at home demonstrated equally low rates (<1%) of recurrent venous 
thromboembolism and all-cause mortality compared to patients treated in-hospital. 
Recently, a simplified version of the PESI has been developed.10 This simple rule, with only 
six items, is much more useful in the busy emergency department.
Our study group recently published the Hestia study: a multicenter study on outpatient 
treatment, which used 11 practical clinical exclusion criteria (Hestia criteria) to select patients 
for outpatient treatment.4 The present study is a post-hoc comparison of the data of the 
Hestia study, in which we applied the simplified PESI (sPESI) to our patients. In this article we 
compare the performance of the Hestia criteria and the sPESI in selecting low-risk PE patients 




This is a post-hoc analysis on data from the Hestia study, which was a multicenter 
prospective cohort study performed in 12 hospitals in The Netherlands. For this analysis we 
selected consecutive patients with acute PE treated as in- or outpatients with anticoagulants 
between 2008 and 2010. Inclusion criteria were: over 18 years of age with proven acute PE 
presenting to the Emergency Department or outpatient clinic. Patients with asymptomatic 
or chronic PE, defined as symptoms > 14 days, without acute worsening, were not included. 
All patients were treated at home with anticoagulants, unless one of the Hestia criteria was 
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present (Table 1). If one of the Hestia criteria was present, the patient was admitted to the 
hospital. The complete methods of this study are described elsewhere.4 The Hestia study was 
approved by the Institutional Review Board of all participating hospitals and patients gave 
informed consent. The patients treated in-hospital were not study patients because they 
were not eligible for the intervention of outpatient treatment. After the study we thoroughly 
reviewed the medical charts of the patients treated in the hospital to investigate whether 
they had had predefined adverse clinical outcome within 3 months after the initial PE, as 
described below. 
Endpoints
All patients were followed for 3 months. Follow-up in the patients treated as outpatients was 
done according to the Hestia study protocol; patients visited the outpatient clinic at 1 week, 
6 weeks and 12 weeks after the initial PE. In the patients treated as inpatients, the endpoints 
were collected by chart review. The primary outcome was recurrent venous thromboembo-
lism during 3 months following the diagnosis of PE. The secondary outcomes were: major 
bleeding and all-cause mortality during 7 days and 3 months. The 30-day all-cause mortality 
endpoint was added after the study was finished, to compare our data with the literature. An 
Table 1. Items in the Hestia criteria and the simplified Pulmonary Embolism Severity Index
Hestia criteria Simplified Pulmonary Embolism Severity Index
1. Hemodynamically instable?* 1. Age > 80 years?
2. Thrombolysis or embolectomy necessary? 2. Cardiopulmonary co-morbidity?
3. High risk for bleeding?** 3. History of cancer?
4. Oxygen supply to maintain oxygen saturation >90% >24 h.? 4. Arterial oxyhemoglobin saturation level <90%?
5. Pulmonary embolism diagnosed during anticoagulant 
treatment?
5. Systolic blood pressure <100 mmHg?
6. Intravenous pain medication >24 h.? 6. Pulse frequency ≥110 beats/min?
7. Medical or social reason for treatment in the hospital >24 h.? 
8. Creatinine clearance of less than 30 ml/min?*** 
9. Severe liver impairment**** 
10. Pregnant?
11. Documented history of heparin induced thrombocytopenia?
If one of the questions is answered with YES,  the patient can not 
be treated at home
If one of the items is present the patient cannot be treated 
at home
* Include the following criteria, but are left to the discretion of the investigator: systolic blood pressure <100 
mmHg with heart rate >100 beats per minute; condition requiring admission to an intensive care unit
** Gastrointestinal bleeding in the preceding 14 days, recent stroke (less than 4 weeks ago), recent operation 
(less than 2 weeks ago), bleeding disorder or thrombocytopenia (platelet count < 75 x 109/L), uncontrolled 
hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg)
*** Calculated creatinine clearance according to the Cockroft-Gault formula
**** Left to the discretion of the physician
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independent adjudication committee adjudicated all outcomes. They also assessed whether 
death was likely to be PE related based on autopsy reports and clinical reports. 
Simplified Pulmonary Embolism Severity Index
In this post-hoc analysis, the sPESI was applied on the data of the Hestia study.10 The sPESI 
consists of six items and if one of the items is present, the patient is considered at high risk 
for 30-day mortality and cannot be treated at home (Table 1). The age, cardiopulmonary co-
morbidity and history of cancer were prospectively registered in out- and inpatients during 
the Hestia study. The pulse frequency, blood pressure and oxygen saturation were collected 
in all patients by chart review. We calculated the proportion of patients who were treated 
at home according to the Hestia criteria, but could not be treated at home according to the 
sPESI and vice versa.    
Statistics
Differences between categorical variables were studied using the Fisher’s Exact test and con-
tinuous variables were compared using an independent samples T-test. A two-sided p-value 
was considered to indicate a significant difference if <0.05. The discriminatory abilities of the 
Hestia criteria and the sPESI were investigated by measuring the area under the curve (AUC) 
in receiver operating characteristics (ROC) analyses. SPSS version 17 (SPSS Inc, Chicago, IL) 
was used for all analysis. 
Results
Patient selection and characteristics
From 2008 to 2010 530 patients were selected; 297 were treated at home in the Hestia 
Study and 243 were excluded from outpatient treatment by the Hestia criteria and treated 
in-hospital. In 468 of 530 patients all items of the sPESI score could be collected from the 
medical charts. This resulted in the inclusion of 247 patients treated at home and 221 patients 
treated in the hospital according to the Hestia criteria in this post-hoc analysis.
The patients treated in the hospital were excluded from outpatient treatment by the fol-
lowing Hestia criteria: medical or social reasons 82 (37%), hypoxia 67 (30%), hemodynamic 
instability 28 (13%), high bleeding risk 14 (6%), intravenous narcotics 11(5%), use of thera-
peutic anticoagulants 7 (3%) and indication for thrombolysis 5 (3%). The reason for hospital 
admission was not specified in 7 patients.
Overall, the patients had a mean age of 58 years and 55% were male. Fifteen percent of 
patients had a history of cancer and 10% had a cardiopulmonary co-morbidity, for example 
heart failure or chronic obstructive pulmonary disease (Table 2).
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Simplified Pulmonary Embolism Severity Index 
The distribution of the items of the sPESI in all patients and the patients treated at home or 
in the hospital is displayed in Table 2. Overall, 275 of 468 patients (59%) were classified as low 
risk according to the sPESI and 193 of 468 patients (41%) were classified into the high risk 
sPESI group. Patients with low risk according to sPESI had significantly lower 30-day mortality 
of 0.4% versus 5.3% in the high risk sPESI patients (p=0.001).  
Of the 247 patients treated at home, 189 (77%) of patients would have been in the low risk 
sPESI group and 58 patients (23%) would have been in the high risk sPESI group. Of the 221 
patients treated in the hospital, 86 (39%) would have been in the low risk sPESI group and 135 
(61%) would have been in the high risk sPESI group. 
Patients with cardiopulmonary co-morbidity, malignancy or age >80 years are defined as 
high risk patients according to the sPESI. In the Hestia study 26% of patients with cardiopul-
monary co-morbidities, 21% of patients with malignancies and 30% of patients >80 years 
could be treated at home, with only one adverse event. One of the patients with pancreatic 
cancer died of end-stage cancer within 30 days (day 29) and the other patients had uncompli-
cated clinical courses. Nine patients died within 30 days in the high-risk sPESI patients treated 
in the hospital (6.8%; 95%CI 3.2-13) versus one in the high-risk sPESI patients treated at home 
(1.7%; 95%CI 0.04-9.2; Table 3).
Test characteristics Hestia criteria versus sPESI
Eleven patients (2.4%) died within 30 days, nine patients treated in-hospital and two patients 
treated at home. None of the patients treated at home died of fatal PE. Of the 11 patients 
that died within 30 days, ten would be classified as high risk according to the sPESI and one 
would have been classified as sPESI low risk. The Hestia criteria had a sensitivity for 30-day 
mortality of 82% and a negative predictive value of 99% (Table 4). The sensitivity of the sPESI 
was 91% and the negative predictive value was almost 100%. Because of the low incidence 
Table 2. sPESI items in patients at home versus patients treated in the hospital






Age >80 43 (9) 9 (4) 34 (15)
History of cancer 69 (15) 21 (9) 48 (22)
Cardiopulmonary co-morbidity 47 (10) 12 (5) 35 (16)
Heart rate ≥110 bpm 76 (16) 22 (9) 54 (24)
Systolic blood pressure <100 mmHg 18 (4) 0 18 (8)
Oxygloblin saturation <90% 33 (7) 2 (0.8) 31 (14)
sPESI low risk 275 (59) 189 (77) 86 (39)
sPESI high risk 193 (41) 58 (23) 135 (61)
Data are displayed as N(%). Bpm=beats per minute; sPESI= simplified Pulmonary Embolism Severity Index 
* 50 patients were excluded because one or more items of the sPESI score were missing
** 12 patients were excluded because one or more items of the PESI score were missing
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of 30-day mortality, the specificity and positive predictive value were low for both clinical 
decision rules: 54% and 4% for the Hestia criteria and 62% and 5% for the sPESI, respectively 
(Table 4). The ROC-curve demonstrated an AUC of 0.756 (95% CI 0.642-0.871) for the sPESI 
and 0.679 (95% CI 0.536-0.822) for the Hestia criteria.
The Hestia criteria identified 53% as low risk and the sPESI would have identified 59% of 
PE patients as low risk. The Hestia low risk patients were all treated at home. Of the patients 
identified as low risk by the sPESI, 86 of 275 (31%) had an indication for hospital admission ac-
cording to the Hestia criteria. The main reasons for hospital admission were: medical or social 
reasons in 34 patients (40%), hypoxia in 24 patients (28%), high bleeding risk in 7 patients 
(8%), intravenous narcotics in 7 patients (8%).  
Table 3. Distribution of adverse clinical events of low and high risk sPESI groups in the patients treated at 
home or in the hospital in the Hestia study
All patients Home treatment Hospital treatment* p-value

















Major bleeding 3 (1.1) 1  (0.5) 2 (2.3) 0.231
Recurrent VTE 4 (1.5) 3 (1.6) 1 (1.2) 1.0

















Major bleeding 9 (4.7) 0 9 (6.8) 0.059
Recurrent VTE 10 (5.3) 2 (3.4) 8 (6.1) 0.726
sPESI= simplified Pulmonary Embolism Severity Index 
* 3 patients lost to follow-up
Table 4. Test characteristics Hestia criteria versus sPESI on 30-day mortality
Hestia criteria sPESI 
Sensitivity 82 (48-97) 91 (57-100)
Specificity 54 (49-59) 60 (56-65)
Proportion identified as high risk 47 (42-51) 41 (36-45)
Proportion identified as low risk 53 (48-58) 59 (54-64)
Negative predictive value 99 (97-100) 100 (98-100)
Positive predictive value 4 (2-8) 5 (3-10)




Our study demonstrated that the Hestia criteria and the sPESI perform equally well in predict-
ing 30-day mortality in patients with acute PE. Both methods safely identified more than half 
of the PE patients as low risk. However, there were also several discrepancies. Most impor-
tantly, a fourth of the patients treated at home safely in the Hestia study would have been 
classified as high risk by the sPESI and therefore would not have been eligible for outpatient 
treatment according to the sPESI. Of importance, none of the patients with a high risk sPESI 
score treated at home in the Hestia study died of fatal PE and two patients died of end-stage 
cancer. On the other hand, 39% of patients identified as low risk by sPESI could not be treated 
at home in the Hestia Study, because of medical or social reasons for hospital admission.
In our study, 59% of PE patients were identified as low risk by the sPESI. This is a high pro-
portion of low-risk patients when compared to the 31-46% reported in the literature.10-13 This 
is mainly due to the lower proportion of patients with malignancies in our study. Two recent 
studies have reported low 30-day mortality rates of 0-0.6% of both low risk (s)PESI patients 
treated at home and low risk patients treated in the hospital.9,11 This is well comparable to 
the mortality of 0.5% in low risk patients treated at home and to the 0% mortality in low risk 
patients treated in the hospital in our study. Our study and the study of Erkens et al. are the 
only studies that describe clinical outcome in PE patients with high sPESI scores treated at 
home. The patients with high PESI scores, selected for home treatment, had markedly lower 
30-day mortality rates than patients with high PESI scores treated in the hospital: 0-2% in 
patients treated at home versus 7-11% in patients treated in the hospital.11 In the majority 
of the patients with high risk sPESI, who were safely treated at home, malignancy was the 
only sPESI risk item present. This suggests that with the use of the clinical criteria like the 
Hestia criteria, a selected group of patients with one of the sPESI risk items, mainly patients 
with cancer, can be safely treated at home. From a clinical perspective this is very important. 
Patients with malignancy already have many intensive oncology therapies in the hospital 
and often have a short life expectancy; therefore every day that can be spent at home is 
of great value to the patient. Moreover, although oncology patients with PE are indeed at 
increased risk of mortality14 and therefore considered as high risk patients by (s)PESI,  most of 
this mortality is not directly related to the PE event but rather to progression of the underly-
ing malignancy. It is, in our view, unlikely that this mortality could be prevented by treating 
these patients as inpatients. 
Our study had some limitations that should be acknowledged. In 62 of 530 patients (12%) 
some of the items of the sPESI score were not recorded and therefore these patients were 
excluded from the analyses. However, follow-up was complete in all of these patients, except 
for one patient living abroad. During follow-up only one of 62 patients died of a pulmonary 
infection. This patient would have been in the high risk sPESI group because of preexisting 
COPD and was admitted to the hospital in the Hestia study because of the need of intra-
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venous antibiotics. The test characteristics of the Hestia criteria and the sPESI in predicting 
30-day mortality would not alter significantly by adding this one case in the high risk sPESI 
group that was treated in-hospital.
Another limitation is that the sPESI was not tested prospectively in our cohort in selecting 
patients for outpatient treatment. Future studies should focus on that.
The PESI is currently the best validated method for risk stratification for PE outpatient 
treatment; however this score has some practical disadvantages. First, before PESI can be 
used in clinical practice, some practical exclusion criteria for hospital treatment have to be 
added to the PESI. In the randomized trial by Aujesky et al. the 11 items of the PESI scored 
after 14 practical exclusion criteria for outpatient treatment were applied, because a part of 
the PESI low risk patients could not be treated as outpatients, because of medical or social 
conditions.9 In this trial physicians had to check 25 items before the patient could be selected 
for outpatient treatment. This triaging is too complicated and time consuming for use in busy 
emergency departments.15 The introduction of the sPESI, with only six risk items, partly solves 
this problem, but still this score cannot directly select patients eligible for outpatient treat-
ment; several practical exclusion criteria have to be added.
Second, due to the many exclusion criteria for outpatient treatment that had to be added 
to the PESI, only 30% of patients with PE could be selected for outpatient treatment.9 When 
using the sPESI instead of the original PESI, the proportion of PE patients eligible for outpa-
tient treatment could be even lower.10,11 
The advantage of using the Hestia criteria for selecting patients for outpatient treatment 
is that more than 50% of PE patients can be treated at home, with equally low mortality 
rates compared to the PESI.4,9 The sPESI generally excludes patients with co-morbidities or 
advanced age on forehand from outpatient treatment. Our study demonstrated that 20-30% 
of all patients with malignancies, cardiopulmonary co-morbidities or elderly patients can be 
safely treated at home, without PE-related mortality. Therefore, we conclude that the Hestia 
criteria appear to offer a more individualized and simple approach in selecting patients for 
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The aim was to compare the Hestia criteria to the European Society of Cardiology (ESC) cri-
teria for selecting low risk patients with pulmonary embolism (PE) for outpatient treatment. 
Methods and results 
From 2008 to 2010, 496 patients with acute, symptomatic PE presented to 12 Dutch hospitals, 
of which 275 were treated at home and 221 were treated in the hospital according to the 
Hestia study protocol. The Hestia criteria were used to select patients for outpatient treat-
ment. Right and left ventricular (RV, LV) diameters were measured on computed tomography 
images. RV dysfunction was defined as a RV/LV ratio>1.0. Patients were classified according 
the ESC criteria in low, intermediate and high risk groups, based on blood pressure and RV 
dysfunction. During 3 months follow-up adverse events were scored.  
Adverse events occurred in 22 patients (4.5%) treated in the hospital versus none of the 
patients treated at home (p<0.001). Sensitivity and negative predictive value for adverse 
outcome were 100% for the Hestia criteria and 83% and 98% for the ESC criteria, respectively. 
Of the patients treated at home according to the Hestia criteria, 34% were normotensive, but 
had RV dysfunction and were classified as intermediate risk according to the ESC criteria. No 
adverse events happened in these patients treated at home. 
Conclusion
Clinical criteria, like the Hestia criteria, could be helpful in selecting patients including those 
with RV dysfunction who have low risk for adverse clinical outcome and could be candidates 
for outpatient treatment.
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Introduction
The presence of right ventricular (RV) dysfunction is an important predictor for short term 
mortality in patients with pulmonary embolism (PE).1 A substantial proportion of normo-
tensive patients with PE have signs of RV dysfunction; proportions up to 60% have been 
reported.2,3 These patients with PE and RV dysfunction have a two to five times higher risk for 
short term mortality than patients without RV dysfunction.2,4-6 
The latest European Society of Cardiology (ESC) guidelines advise to perform initial risk 
stratification in patients with PE to distinguish patients with high risk for short term mortality 
from those with non-high risk (Grade IB recommendation).7 High risk patients are defined as 
having cardiovascular shock or persisting hypotension and they have a mortality risk >30%.8 
Normotensive patients are considered as non-high risk patients, with a lower risk for short 
term mortality of 2-15%.9-11 In non-high risk patients further risk stratification to interme-
diate and low risk groups can be performed. Imaging (e.g. computed tomography (CT) or 
echocardiography) or laboratory markers ((NT-pro)BNP or troponins) have been proposed 
in distinguishing low from intermediate risk patients.6 Low risk patients are defined by the 
absence of any signs of right ventricular (RV) dysfunction or myocardial ischemia on imag-
ing and/or laboratory tests. These patients have a very low risk for short term mortality of 
less than 1%.4 The ESC guidelines recommend the restriction of PE outpatient treatment to 
patients with low risk, determined by laboratory or imaging parameters.7 Importantly, these 
criteria are based on consensus and lack prospective validation in clinical practice. 
From 2008-2010 we performed the Hestia study: a study on the safety of initial outpatient 
treatment in patients with PE.12 PE patients were selected for outpatient treatment with the 
Hestia criteria, a set of 11 clinical criteria (Table 1). The present study compared two methods 
for selection of patients for outpatient treatment: the Hestia Criteria and the ESC criteria. 
Our hypothesis was that a part of the intermediate risk patients, as defined by the ESC crite-
ria, with the advice to be hospitalized, could be safely treated at home in the Hestia study. 
Therefore, the aim of this study was to describe the distribution of low, intermediate and high 
risk patients (according to the ESC criteria), assessed with blood pressure combined with RV 
dysfunction measured on CT, and the clinical outcome among the patients treated at home 





This study was a post-hoc analysis on data from the Hestia study, a multicenter prospective 
cohort study performed in twelve Dutch hospitals from May 2008 till April 2010.12 In this study 
patients with acute PE were selected for anticoagulant treatment at home according to the 
Hestia criteria, which are 11 clinical selection criteria based on signs and symptoms. Patients 
who were not eligible for outpatient treatment were admitted to the hospital for treatment 
with anticoagulants. The complete methods of the Hestia study are described elsewhere.12 
The Hestia study was approved by the Institutional Review Board of all participating hospitals 
and patients gave informed consent. The patients treated in the hospital were not study pa-
tients because they were not eligible for the intervention of outpatient treatment. After the 
study we reviewed the medical charts of the patients treated in the hospital to investigate 
whether they had had adverse clinical outcome within 3 months after the initial PE. 
Patients
Consecutive patients with acute PE treated as in- or outpatients with anticoagulants were 
selected for this post-hoc analysis. Inclusion criteria were: over 18 years of age with proven 
acute PE presenting to the Emergency Department or outpatient clinic. Patients with asymp-
tomatic or chronic PE, the latter defined as duration of symptoms existing longer than 14 
Table 1: Hestia criteria
HESTIA CRITERIA
1. Hemodynamically instable?*
2. Thrombolysis or embolectomy necessary?
3. Active bleeding or high risk for bleeding?**
4. Oxygen supply to maintain oxygen saturation >90% >24 h.?
5. Pulmonary embolism diagnosed during anticoagulant treatment?
6. Intravenous pain medication >24 h.?
7. Medical or social reason for treatment in the hospital >24 h.? 
8. Creatinine clearance of less than 30 ml/min?*** 
9. Severe liver impairment?**** 
10. Pregnant?
11. Documented history of heparin induced thrombocytopenia?
If one of the questions is answered with YES, the patient can NOT be treated at home
* Include the following criteria, but are left to the discretion of the investigator: systolic blood pressure <100 
mmHg with heart rate >100 beats per minute; condition requiring admission to an intensive care unit
** Gastrointestinal bleeding in the preceding 14 days, recent stroke (less than 4 weeks ago), recent operation 
(less than 2 weeks ago), bleeding disorder or thrombocytopenia (platelet count < 75 x 109/L), uncontrolled 
hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg)
*** Calculated creatinine clearance according to the Cockroft-Gault formula
**** Left to the discretion of the physician
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days and no acute worsening within the last 14 days, were not included. If patients had a 
proven PE on CT and none of the Hestia criteria (Table 1) were present, informed consent 
was asked for participation in the outpatient study. If one of the Hestia criteria was present 
or informed consent was refused, the patient was admitted to the hospital for anticoagulant 
treatment.
Endpoints
All patients were followed for 3 months. Follow-up in the patients treated as outpatients 
was done according to the Hestia study protocol; patients visited the outpatient clinic at 1 
week, 6 weeks and 3 months after the initial PE. In the patients treated as inpatients, the end-
points were collected by chart review. The outcomes of interest were the occurrence of one 
of the following clinical adverse events: PE related mortality, resuscitation after respiratory 
or cardiac arrest, need for mechanical ventilation or use of inotropic agents, administration 
of thrombolytic drugs or surgical embolectomy.13 An independent adjudication committee 
assessed whether death was likely to be PE related based on autopsy reports and clinical 
reports. All-cause mortality was reported at 1 week and 3 months according to the initial 
Hestia study protocol. The 30-day mortality was added to the outcomes to compare our data 
to the ESC guidelines.7  
Procedures   
Most of the patients underwent computed tomography pulmonary angiography (CTPA) to 
confirm the diagnosis of PE, but other imaging modalities were also allowed in the Hestia 
study protocol. CTPA was performed by the CT equipment of the local hospitals. CT scan-
ners of various vendors were used (Toshiba, Philips, Siemens, GE). Multi-slice non-ECG-gated 
helical CT with 4, 16, and 64-slice scanners were used with a slice thickness of 1 mm (64-slice 
scanners) or 2 mm (4 and 16-slice scanners). Tube voltage was 120-140 kV and tube current 
was 150-400 mA.
Left and right ventricle diameters were measured for calculation of the RV/LV ratios. The 
ventricular diameters were measured in the transverse plane at the widest points between 
the inner surface of the free wall and the surface of the interventricular septum (Figure 1).3 
The maximum diameters could be found at different levels in the right and the left ventricle.
Right ventricular dysfunction was considered absent if the RV/LV ratio was 1.0 or less, mod-
est RV dysfunction was defined as a ratio greater than 1.0, but less or equal to 1.5 and severe 
RV dysfunction was defined as a ratio greater than 1.5.3 
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Ventricular diameter measures and reproducibility
The measuring of the ventricular diameters was performed on different post-processing 
workstations in standard axial views by one observer (WZ). This observer was trained and 
supervised by a radiologist with 11 years of experience on thoracic/cardiac CT imaging (LK). 
The observers were blinded for the clinical conditions of the patients and for information 
regarding treatment at home or in the hospital. For logistic reasons, one observer (WZ) 
visited all 12 hospitals for measuring LV and RV diameters on the CT-images. As to determine 
reproducibility for ventricular diameter measurements, a pilot study was performed to as-
sess interobserver agreement. In addition intraobserver agreement of both observers was 
assessed to show the consistency of the LV and RV measurements. To calculate the intra- and 
interobserver agreement, a random sample of the CT scans (n=86) was measured by the two 
observers and the correlation coefficient was calculated. Intra- and interobserver agreement 
were classified based on the magnitude of the correlation coefficient: <0.2 poor agreement, 
0.21-0.40 fair agreement, 0.41-0.60 moderate agreement, 0.61-0.80 good agreement, 0.81-1.0 
very good agreement. Only if the correlation coefficient showed at least a good agreement 
(0.61), the pilot study would be extended with the measurements of CT-scans in the other 
hospitals. When comparing the observations between both observers, the interobserver 
agreement, the correlation coefficients were 0.899 for the LV diameter, 0.944 for the RV diam-
Figure 1: Right and left ventricular diameters measured on transversal CT-image
A: right ventricle diameter B: left ventricle diameter
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eter and 0.682 for the RV/LV ratio (p< 0.001 for all correlations). This corresponds with good 
(>0.61) to very good (>0.81) agreement.
When comparing both measurements of observer WZ, the correlation coefficients were 
0.941 for LV diameter, 0.891 for RV diameter and 0.902 for RV/LV ratio (p<0.001 for all). For 
observer LK, the correlation coefficients were 0.933 for LV diameter, 0.928 for RV diameter 
and 0.768 for RV/LV ratio (p<0.001 for all correlations). The intraobserver agreement calcula-
tions showed good to very good agreement in both observers.
Risk classification
Patients were divided in three risk groups according to the ESC guidelines.7 Patients were 
considered to have low risk for mortality if they were hemodynamically stable and had no 
signs of RV dysfunction (RV/LV ratio<1.0). Patients were considered to be of intermediate risk 
if they were normotensive, but had signs of RV dysfunction on the CT-scan (RV/LV ratio>1.0). 
Patients were considered as high risk patients if they presented to the Emergency Depart-
ment in cardiovascular shock or had a systolic blood pressure lower than 100 mmHg or were 
classified as being hemodynamically unstable by the local physician, irrespective of RV/LV 
ratio. 
Statistics
Pearson correlation was used to calculate the correlation coefficient to determine the in-
tra- and interobserver agreement in the pilot study. We evaluated the clinical utility of the 
Hestia criteria and the ESC criteria by assessing the specific test characteristics for predicting 
adverse events. Differences between categorical variables were studied using the Fisher’s 
Exact test when comparing two groups and Chi Squared test when comparing three groups. 
Continuous variables were compared using an independent samples T-test. The association 
between RV dysfunction/ESC risk groups and adverse clinical outcome was studied by calcu-
lating odds ratios (OR) by logistic regression, adjusted for age, gender and cardiopulmonary 
co-morbidity. A two-sided p-value <0.05 was considered to indicate a significant difference. 
SPSS version 17 (SPSS Inc, Chicago, IL) was used for all analyses. 
Results
Patients
From 2008 to 2010, 530 patients with acute, symptomatic PE presented to 12 Dutch hospitals. 
Of these patients 297 were treated at home and 233 were admitted to the hospital. In 34 
patients (6%) the CT parameters could not be measured, because ventilation/perfusion scan 
was used to diagnose PE (n=18) or due to technical problems (n=16). This resulted in 496 
patients with CT-scans available for evaluation, 275 patients treated at home and 221 treated 
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in the hospital. Three patients treated in the hospital were lost to follow-up during the 3 
months of follow-up, because they lived abroad.
Patients had a mean age of 58 years and 54% of patients were male, 7% of patients had 
COPD and 3% of patients had heart failure. Patients treated in the hospital were older and 
had a higher percentage of co-morbidity (Table 2). Patients treated at home had a higher 
systolic blood pressure (143 vs. 134 mmHg, p<0.001) and a lower heart rate (87 vs. 95 beats 
per minute, p<0.001) at presentation. The mean duration of hospital admission was 7 days in 
the patients who were treated in the hospital. 
Adverse clinical outcome
All-cause mortality during 3 months following the diagnosis of PE was 4.7% and 47% of 
mortality happened within the first month (Table 2). All of the 22 (4.5%) patients who had 
Table 2: Baseline characteristics of patients with pulmonary embolism treated at home versus patients 









P-value home vs 
hospital treatment
Age (years) 58 ± 17 55 ± 16 62 ± 17 <0.001
Male sex 268 (54%) 159 (58%) 109 (49%) 0.07 
Heart failure 13 (2.6%) 1 (0.4%) 12 (5.5%) <0.001
COPD 32 (6.5%) 10 (3.6%) 22 (10%) 0.005
Systolic blood pressure (mmHg) 138 ± 24 143 ± 21 134 ± 26 <0.001
Diastolic blood pressure (mmHg) 82 ± 15 85 ± 14 80 ± 16 <0.001
Heart rate (bpm) 91 ± 19 87 ± 15 95 ± 22 <0.001
RV/LV ratio 1.1 ± 0.3 0.99 ± 0.2 1.2 ± 0.4 <0.001
No RV dysfunction 271 (55%) 180 (66%) 91 (41%) <0.001































PE related mortality 5 (0.9%) 0 5 (2.3%) 0.016






















Continuous variables are displayed as mean (standard deviation(sd)) and categorical variables are displayed as 
number (percentage); bpm= beats per minute; COPD= chronic obstructive pulmonary disease; LV = left ventricle; 
RV= right ventricle; CPR=cardiopulmonary resuscitation **3 patients lost-to-follow-up 
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one or more adverse events during 3 months follow-up, were patients treated in the hospital: 
six patients were ventilated mechanically, six patients underwent cardiopulmonary resus-
citation (CPR), 16 had thrombolysis and six needed inotropic medication for hemodynamic 
problems caused by the pulmonary embolism (Table 2). 
Right ventricular dysfunction in patients treated at home or in the hospital
In Table 2 RV and LV parameters are presented. RV/LV ratio was lower in patients treated at 
home than in patients treated in the hospital (0.99 vs. 1.2, p<0.001). In the total group of 
496 patients, 225 (45%) had right ventricular dysfunction defined as a RV/LV ratio>1.0: 34% 
had modest RV dysfunction (RV/LV ratio 1.0-1.5) and 11% had a severe RV dysfunction (RV/
LV ratio >1.5). A significant lower proportion of patients treated at home had RV dysfunc-
tion compared to patients treated in the hospital (35% vs. 59%, p<0.001). Patients treated 
in the hospital had a higher proportion of patients with severe RV dysfunction (20% vs. 4%, 
p<0.001). None of the patients with a severe RV dysfunction who were treated at home had 
an adverse event.  
RV dysfunction was significantly associated with adverse events. Patients with modest RV 
dysfunction had a six times higher risk for adverse events compared to patients without RV 
dysfunction (OR 5.8, 95%CI 1.1-29; p=0.03) and patients with a severe RV dysfunction had a 
47 times higher risk for adverse events compared to patients with no RV dysfunction (OR 47, 
95%CI 9-238; p<0.001). RV dysfunction was not significantly associated with all-cause mortal-
ity nor with PE related mortality. 
Test characteristics of Hestia criteria versus ESC criteria
The discriminative power of both selection methods are underlined by a high sensitivity for 
adverse events: 100% (95% CI 82-100) in the Hestia criteria and 83% (95% CI 64-93) in the 
ESC criteria. Both methods also had a high negative predictive value: Hestia criteria 100% 
(95% CI 98-100) and ESC criteria 98% (95% CI 95-99). The specificity and positive predictive 
values were 58% (95% CI 54-63) and 10% (95% CI 7-15) for the Hestia criteria and 56% (95% 
CI 52-61) and 11% (95% CI 7-16) for the ESC criteria. Both the Hestia criteria and the ESC 
criteria selected more than half of patients as low risk and potentially eligible for outpatient 
treatment (55% and 54%).
Comparison of patients selected as low risk by Hestia or ESC criteria 
Overall, 54% of patients were normotensive and had no RV dysfunction and could therefore 
be classified in the ESC low risk group. In addition, 39% of patients were normotensive with 
RV dysfunction and classified as intermediate risk and 7% of patients were hemodynamically 
unstable and classified as high risk
Of the 275 patients treated at home according to the Hestia criteria, 180 (65%) belonged 
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one (0.4%) to the high risk ESC group (Figure 2). None of the outpatients had an adverse 
event. Three outpatients died during 3 months of non-PE related causes: one of intracranial 
bleeding (day 8) and two of end-stage pancreatic cancer (day 29, 59).
Of the 221 patients treated in the hospital according to the Hestia criteria, 88 (40%) be-
longed to the low risk ESC group, 100 (45%) belonged to the intermediate risk group and 
33 (15%) to the high risk group. The main reasons for hospital admission due to the Hestia 
criteria in patients selected as low risk, according to the ESC criteria, were medical (mainly 
co-morbidities) or social reasons for hospital admission (51%) and need for oxygen supply 
to maintain adequate oxygen saturation (24%). The risks for adverse events were higher in 
all three risk groups treated in the hospital versus the risks of adverse events of the patients 
treated at home (Figure 2).   
Discussion
Our study shows that the Hestia criteria and the ESC criteria had both good discriminative 
power to select patients with low risk for adverse events for outpatient treatment (negative 
predictive values of 100% and 98%). Of note, 34% of patients treated at home in the Hestia 
study had RV dysfunction, demonstrated by an increased RV/LV ratio at CTPA. These patients 
would have been excluded from outpatient treatment by the ESC criteria, but were treated 
at home safely in the Hestia study, without PE related adverse events. This study is the first 
to describe a group of patients with RV dysfunction, who have been safely treated at home. 
Both the Hestia criteria and the ESC criteria safely selected more than 50% of PE patients 
as low risk and potentially eligible for initial outpatient treatment. The Hestia criteria consist 
of risk markers for adverse outcome (e.g. hemodynamic status, hypoxia) combined with 
practical criteria to select PE patients for outpatient treatment. The Hestia criteria can be 
implemented in clinical care without changes. The ESC criteria, however, only consist of risk 
markers for adverse clinical outcome. Some patients with PE can not be treated at home 
for medical or social reasons unrelated to PE. Before the ESC criteria can be used in clinical 
practice for selection of PE patients for outpatient treatment, practical exclusion criteria have 
to be added. This would decline the proportion of patients with PE treated at home to less 
than 50%. 
Both echocardiography and CT can be used to establish RV dysfunction, since both meth-
ods have a high negative predictive value of 92-99%, which is important in selecting low risk 
PE patients.14 In this study CT was used to establish RV dysfunction. The advantage of CT over 
echocardiography is that it can be used as a diagnostic and prognostic method in the same 
procedure and is generally available.  
This study also has some limitations. First, while the Hestia criteria were applied pro-
spectively in the Hestia study, the ESC criteria were determined in a post-hoc fashion. As 
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a consequence, only hemodynamic status and the presence of RV dysfunction on CT scan 
were used to classify patients to the low, intermediate or high risk ESC groups. In the ESC 
consensus document it is suggested to add biomarkers of myocardial ischemia, including 
troponins. It is stated in the literature that the addition of troponin testing improves test 
characteristics.15 Troponins were not measured in the Hestia study. However, because no PE 
related adverse events happened in the patients treated at home, adding troponins to the 
selection of patients for outpatient treatment could not have increased the high negative 
predictive value of 100%. 
Second, right and left ventricle diameters were measured by one investigator. However, 
the interobserver agreement in a subset of patients was good. In addition, the 45% propor-
tion of PE patients with RV/LV ratio >1.0 is well comparable to previous reported proportions 
of 38-58%.3,16   
Third, although RV dysfunction was significantly associated with the occurrence of adverse 
events, we were unable to repeat the association between RV dysfunction and PE related 
mortality described in the literature.3 The lack of a significant association between RV dys-
function and fatal PE is probably due to the low number of fatal PE in our study.
What are the implications of our findings? The ESC guidelines recommend restriction of PE 
outpatient treatment to patients with low risk, determined by laboratory or imaging param-
eters and to hospitalize those with signs of RV dysfunction. As none of the hemodynamically 
stable patients, with or without RV dysfunction, treated at home in the Hestia study had a 
PE related adverse event, our results strongly suggest that a proportion of patients with RV 
dysfunction can be pre-identified, who could be treated at home safely. Clinical criteria, like 
the Hestia criteria, could be helpful in selecting patients with RV dysfunction who have a 
very low risk for adverse clinical outcome and could be candidates for outpatient treatment. 
Ideally prospective studies comparing the ESC criteria and the Hestia criteria are needed to 
corroborate our findings. 
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Many studies show that NT-proBNP at diagnosis of pulmonary embolism (PE) can be used to 
discriminate patients at low risk for adverse outcome after PE. The first aim of this study was 
to describe the course of NT-proBNP one week after PE. The second aim was to investigate 
whether adding a NT-proBNP test at day 2 to the test at day 1 would increase the predictive 
value for adverse events after pulmonary embolism.
Methods
Prospective cohort study with patients admitted for PE. NT-proBNP levels were measured 
daily. Primary outcome was adverse events during the first week, defined as PE-related mor-
tality or clinical deterioration. 
Results
Of 67 patients, nine patients (13%) had adverse events: seven on day 1, two on day 2. The 
median NT-proBNP level of patients with an event was higher during the first 3 days than of 
patients without an event. A proBNP cut-off >500 pg/mL on day 1 selected 41% of patients as 
low risk. A proBNP cut-off >1800 pg/mL on day 2 selected 62% of patients as low risk.
Conclusion
Repeated NT-proBNP testing within 48 hours after presentation with PE can identify 20% 
extra patients with PE as low risk than when using a single measurement at day 1. These 
patients could be possible candidates for outpatient treatment. It remains to be seen how 
these results translate into clinical practice, since all adverse events occurred within 48 hours.
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Introduction
NT-proBNP (N-terminal brain natriuretic peptide) has been extensively investigated in the lit-
erature as a prognostic factor for an adverse outcome in pulmonary embolism (PE)1-6. Patients 
with an elevated NT-proBNP at the time of diagnosis of PE have a seven times higher risk for 
an adverse outcome than patients with a low NT-proBNP. 
A recently published prospective cohort study has shown that outpatient treatment in 
patients presenting with acute hemodynamically stable PE and NT-proBNP levels <500 pg/
mL is safe with regard to short-term mortality.7 None of the 152 patients with PE and NT-
proBNP levels <500 pg/mL died within 10 days (negative predictive value (NPV) 100%). This 
high NPV has also been observed in other studies.2-4 However, when using the cut-off of 500 
pg/mL only 43% of PE patients can be treated at home.7 The first aim of the present study 
was to describe the course of NT-proBNP levels within one week after the diagnosis of PE. The 
second aim was to investigate whether adding a NT-proBNP test at day 2 to the test at day 1 
would increase the predictive value for adverse events after PE. 
Methods
We conducted a cohort study in a large teaching hospital in the Netherlands from April 
2006 to June 2008. Patients with objectively proven, acute PE admitted to the hospital were 
included. Patients who died before the diagnosis of PE was established and patients trans-
ferred for treatment to another hospital were excluded. PE was demonstrated by imaging 
according to the local diagnostic guidelines (high probability ventilation-perfusion scan 
or abnormal CT-scan). Patients were treated with anticoagulants according to the current 
international guidelines.8 NT-proBNP levels were measured every morning using the Elecsys 
proBNP electrochemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany). 
Adverse events (defined as PE or major bleeding related mortality, cardiopulmonary resus-
citation, mechanical ventilation, use of vasopressors, thrombolytic therapy, thrombosuction, 
open surgical embolectomy and PE or major bleeding related admission to Intensive Care (IC) 
unit) were collected during the first week.3  
For the first aim of the study, to describe the course of NT-proBNP levels after the diagnosis 
of PE, all patients with acute PE were included. For the second aim of the study patients who 
had an adverse event during the first day were excluded. In order to find the NT-proBNP 
cut-off on the second day that would be most predictive for adverse events, we calculated 
test characteristics (sensitivity and specificity) of various absolute cut-off levels of NT-proBNP 
on day 2.   
Differences in baseline characteristics and course of NT-proBNP levels between groups 
were examined by Mann-Withney U statistics for continuous variables and χ2 statistics for 
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categorical variables. The Fisher’s Exact test was used if the count was less than five. SPSS 
version 17.0 (SPSS Inc., Chigago, IL, USA) was used for all analyses. The study was approved 
by the local review board and all patients gave informed consent.
Results
In total 67 patients with acute PE were included. The median age was 63 years and 43% were 
male (Table 1). None of the patients had a history of heart failure. 
Nine patients (13%; 95% CI 6.9-25.4%) had adverse events during the first week, seven 
(78%) on day 1 and two (22%) on day 2. More than 48 hours after presentation with PE no fur-
ther events happened. Eight patients with an adverse event were treated with thrombolytics, 
and in one patient surgical embolectomy was performed, because of high bleeding risk. All 
patients with an adverse event recovered completely.    
Patients with adverse events during follow-up had significant lower systolic blood pressure 
(117 vs. 137 mmHg, p=0.01) and oxygen saturation (84% vs. 95%, p=0.003) at presentation 
than patients without adverse events. The difference in the course of NT-proBNP in PE pa-
tients with and without an adverse event is described in Table 2. The median NT-proBNP level 
of patients with an event was higher during the first three days than of patients without an 
event, but after the third day these differences in the median NT-proBNP levels disappeared 
(Figure 1). The median peak NT-proBNP levels of patients with an adverse event were higher 
than of patients without an adverse event (3181 vs. 1399 pg/mL, p=0.01). Most of the patients 
(85%) had reached the highest level of NT-proBNP within 48 hours after the diagnosis of PE.   
Of the total of 67 patients, four patients were already hemodynamically unstable or had 
clinical deterioration before the first measurement of NT-proBNP. When these four patients 








Age (year) 63          (50-73) 52           (42-62) 65          (51-74) P=0.081
Male sex n(%) 29          (43) 2             (22) 27          (47) P=0.280
SBP (mmHg) 134        (125-151) 117         (93-132) 137        (128-153) P=0.014
Heart Rate (bpm) 88          (74-105) 92           (82-116) 88          (70-105) P=0.130
Oxygen saturation* (%) 94          (89-97) 84           (79-90) 95          (90-97) P=0.003
Heart Failure n(%) 0            (0) 0             (0) 0            (0) -
COPD n(%) 6            (9) 0             (0) 6            (10) P=0.587
Cancer n(%) 11          (16) 0             (0) 11          (19) P=0.336
SBP=systolic blood pressure, bpm= beats per minute, n=number. Continuous data are displayed as median (25th 
percentile-75th percentile). *Patients in whom oxygen saturation was measured while on oxygen suppletion 
were removed from this analysis (N=10). 
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NT proBNP at diagnosis of PE
(N=66)
910        (195-2367) 1823     (617-3456) 703        (178-2187) P=0.153
NT proBNP day 2
(N=63)
1016      (195-3181) 2953    (2301-6600) 749        (160-2215) P=0.004
NT-proBNP day 3
(N=48)
889        (221-2799) 2632    (1009-3557) 769        (186-2545) P=0.088
NT-proBNP day 4
(N=40)
508        (243-1121) 512      (264-1574) 508        (177-1121) P=0.892
NT-proBNP day 5
(N=34)
448        (186-853) 214      (117-1271) 459        (191-819) P=0.738
NT-proBNP day 6
(N=28)
460        (128-794) 484      (100-867) 460        (177-767) P=1.000
NT-proBNP day 7
(N=25)
433        (159-768) 101      (60-1437) 478        (237-768) P=0.231
Peak NT-proBNP 1897      (297-3397) 3181    (2421-5876) 1399      (259-3163) P=0.011
Proportion patients with peak NT-proBNP 
< 48 hours
55          (85) 8          (89) 47          (84) P=1.000
Proportion patients with increase in NT-
proBNP from day 1 to day 2
32          (51) 7          (88) 25          (46) P=0.053
Proportion patients with increase NT-
proBNP >50% from day 1 to day 2
18          (29) 5          (63) 13          (24) P=0.039
NT-proBNP levels are given in pg/mL. Continuous data are displayed as median (25th percentile-75th percentile) 
and categorical data are displayed as number (percentage). 
Figure 1. Course of NT-proBNP
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were excluded from the analysis, 63 patients remained, of which five patients (7.9%; 95%CI 
3.0-17.6%) had an adverse event. Of the 36 patients with NT-proBNP >500 at day 1 (57%), 
five patients got adverse events during hospital admission versus none in the patients with 
NT-proBNP <500 pg/mL (14% vs. 0%; p=0.06).
NT-proBNP cut-off of 1800 pg/mL at day 2 showed the highest sensitivity and specificity for 
adverse events at day 2 (sensitivity 100% (95% CI 46-100%), specificity 65% (95% CI 51-77%)). 
When adding the cut-off of 1800 pg/mL at day 2 to the cut-off of 500 pg/mL at day 1, an 
extra 13 patients (21%) at low risk for adverse events could be added to the 26 (41%) patients 
already selected as low risk at day 1. When combining two different NT-proBNP cut-off levels 
at day 1 and 2, 39 of 63 patients (62%; 95% CI 50-73%) could be selected as low risk patients 
within two days after the diagnosis of PE.   
Discussion
In this study the course of NT-proBNP levels within one week after the diagnosis of PE was 
studied. We investigated whether patients with low proBNP on day 1 or day 2 could be can-
didates for outpatient treatment. Some hypothesis generating observations could be made: 
patients with upcoming adverse events have higher NT-proBNP levels during the first three 
days after PE and have a higher median peak NT-proBNP level than patients with an unevent-
ful clinical course. This study is the first to describe the course of NT-proBNP more than 24 
hours after diagnosis of PE. Only one other study has reported on repeated NT-proBNP test-
ing after PE, but only within 24 hours and concluded that persistent elevation in NT-proBNP 
levels within 24 hours after PE has a high positive predictive value for mortality.9 Our results 
show that repeated NT-proBNP testing, as compared to single testing, could play a role in 
the further selection of low risk patients, who could be candidates for early discharge: when 
combining two cut-off levels for NT-proBNP on day one and day two, 62% (95% CI 50-73%) 
of patients could be classified as being low risk for adverse events. This is higher than the 
average proportions of 42-43% of patients with low risk described in the literature with single 
testing.3,7
The small population is a limitation of this study. Because of this the cut-off on day 2 was 
based on only two adverse events. In larger populations the cut-off with the highest sensi-
tivity and specificity could be different. The limited availability of NT-proBNP tests in some 
hospitals may reduce generalisibility of our results. 
Our results generated the hypothesis that with an extra NT-proBNP test on day 2, a larger 
proportion of low-risk PE patients (62%) can be selected as possible candidates for early 
discharge within 48 hours after the diagnosis of PE. However, since in our study all adverse 
events in this small population of PE patients happened within 48 hours after the diagnosis 
of PE, we cannot decide on whether two day-testing is sufficient to exclude adverse outcome 
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occurring later on. Therefore, the usefulness of repeated NT-proBNP testing for clinical prac-
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The aim of this study was to assess the long term risk for adverse events after acute pulmo-
nary embolism (PE).
Methods 
Consecutive patients diagnosed with PE between January 2001 and July 2007, and patients 
in whom PE was ruled out from a previous study were followed until July 2008 for the oc-
currence of adverse clinical events: mortality, symptomatic recurrent venous thromboem-
bolism (VTE), cancer, arterial cardiovascular events and chronic thromboembolic pulmonary 
hypertension (CTEPH). Hazard ratios (HR) for all endpoints and a combined endpoint were 
calculated and adjusted for potential confounders.
Results 
308 patients with unprovoked, 558 with provoked and 334 without PE were studied with a 
median follow-up period of 3.3 years. Patients with unprovoked PE had lower overall risk for 
mortality than patients with provoked PE (HR 0.59, 95% CI 0.43-0.82), but higher risk for non-
malignancy related mortality (HR 1.8, 95% CI 1.3-2.5), recurrent VTE (HR 2.1, 95% CI 1.3-3.1), 
cancer (HR 4.4, 95% CI 2.0-10), cardiovascular events (HR 2.6, 1.5-3.8) and CTEPH (1.5% vs. 
0%). The risk for the combined endpoint did not differ between both groups (HR 0.98, 95% 
CI 0.82-1.1). Patients without PE had similar risks for malignancy and cardiovascular events 
than patients with provoked PE, but lower risks for the remaining outcomes. The fraction of 
both patients with provoked and unprovoked PE without events after 1 year was only 70%, 
and decreased to fewer than 60% after 2 years and fewer than 50% after 4 years, whereas this 
latter was 84% for the control patients.
Conclusion
The clinical course of acute PE is complicated by high rates of serious adverse events, which 
occur in half of the patients within 4 years.
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Introduction
Acute pulmonary embolism (PE) is a common and potentially serious medical condition.1 
The interaction of an extensive pulmonary artery obstruction rate and presence of cardio-
pulmonary comorbidity may lead to right ventricular dysfunction, which is associated with 
hemodynamic instability and, in severe cases, with death.2 This PE attributable mortality oc-
curs in approximately 2-6% of patients with hemodynamically stable PE and in 30% or more 
of patients with PE presenting with hemodynamic instability or in shock.2-4 Of note, 25% of 
the patients do not survive the first year after diagnosis, although the majority of deaths 
during this time are related to underlying conditions, such as cancer or chronic heart disease, 
rather than to PE itself.3,4 Even after surviving the acute episode, the clinical course of acute 
PE can be complicated by several thrombotic and non-thrombotic adverse events. Bleed-
ing complications and recurrent episodes of venous thromboembolism (VTE) are common 
and chronic obstruction of the pulmonary vessels with organized blood clots may lead to 
chronic thromboembolic pulmonary hypertension (CTEPH).3,5-8 This latter disease is further 
characterized by pulmonary arteriopathy and progressive right heart failure.6 Furthermore, 
it has been well established that patients with acute PE are at higher risk of being subse-
quently diagnosed with cancer as well as with arterial cardiovascular events than population 
controls.9,10 The prognosis of patients diagnosed with unprovoked PE, i.e. PE occurring in the 
absence of established risk factors or predisposing illnesses, might be less favourable than 
that of patients suffering from provoked PE. Several studies have shown that patients with 
unprovoked PE are at particular risk for recurrent PE, CTEPH, arterial cardiovascular events 
and the detection of cancer.9,11-18
Although all individual complications of PE have been studied extensively, the combined 
risk for all adverse clinical events has not been reported yet. Knowledge of this short and long 
term prognosis after acute PE is of great importance since this should guide clinical decision 
making regarding treatment regimes, specific preventive screening programs and follow-up 
duration. Accordingly, we have performed a prospective cohort study evaluating the overall 
occurrence of complications in the clinical follow-up of patients diagnosed with acute PE. 
We contrasted the studied complication rate in patients with unprovoked PE to patients with 
provoked PE and to a control group of patients in whom PE was suspected but ruled out. 
Methods
Patients
The original admission charts of all consecutive in- and outpatients diagnosed with acute PE 
between January 1st 2001 and July 1st 2007 in an academic (LUMC, Leiden, the Netherlands) 
and affiliated teaching hospital (Medical Center Haaglanden, The Hague, the Netherlands) 
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were systematically reviewed using predefined criteria for the diagnosis of acute PE, i.e. 
intraluminal filling defects on pulmonary angiography or computed tomography pulmonary 
angiography (CTPA), high probability ventilation perfusion scintigraphy (V/Q-scan) or inter-
mediate probability V/Q-scan in combination with objectively diagnosed deep vein throm-
bosis (DVT).14,19 All patients fulfilling these criteria were included in this analysis. Patients 
were initially treated with at least 5 days of either unfractionated heparin or weight based 
therapeutic doses of low molecular weight heparin, followed by vitamin K antagonists for a 
period of at least 6 months with a target international normalized ratio (INR) of 2.0 to 3.0.20 
In patients with severe acute PE presenting with hemodynamic instability, anticoagulant 
treatment was preceded by administration of thrombolytic drugs, thrombosuction or surgi-
cal embolectomy according to the judgment of the attending clinician. The control cohort 
consisted of patients in whom PE was clinically suspected but ruled out by either an unlikely 
probability (Wells rule ≤4 points) in combination with a normal high sensitive D-dimer test 
or a CT scan without signs of PE. These patients were recruited for participation in a previous 
outcome study between November 2002 and September 2004.21 
Procedures
Detailed information regarding diagnostic management, cause, treatment and documented 
clinical course of the index PE were extracted from the medical charts of the included pa-
tients with and without PE. When a patient had died, the pathology report was scrutinized 
to establish the cause of death. In case autopsy was not performed, the likely cause of death 
was verified with the treating physician or general practitioner. All surviving patients were 
contacted by mail or phone and were asked to complete our data with the latest information 
regarding their medical history and clinical condition. Patients living abroad or for whom 
up-to-date contact specifications were not available were excluded. This study was approved 
by the Institutional Review Board of both participating hospitals and all patients provided 
informed consent. 
Outcome
Unprovoked PE was defined as PE occurring in the absence of the following risk factors: ac-
tive malignancy, immobility more than 3 days or recent long flight, recent surgery or fracture 
of extremity, pregnancy or peri-partum period and use of oral contraception or hormone 
replacement therapy.1 All-cause mortality, symptomatic recurrent VTE, i.e. acute PE as well 
as deep vein thrombosis, CTEPH, arterial cardiovascular events or detection of a previously 
unknown malignancy were considered to be adverse events in the clinical course of acute 
PE. Only information on anticoagulant related fatal bleeding was available. Recurrent PE 
was defined as 1) a new filling defect revealed by pulmonary angiography or spiral CTPA or 
2) a new high probability perfusion defect revealed by VQ-scan or 3) any new defects after 
earlier normalizing of the scan.5,7 Criteria for the diagnosis of CTEPH were mean pulmonary 
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artery pressures assessed by right heart catheterization exceeding 25 mmHg respectively 
and normal pulmonary capillary wedge pressure in combination with an abnormal perfusion 
scintigram and signs for CTEPH on pulmonary angiography.6 Arterial cardiovascular events 
were defined as clinically adjudicated acute myocardial infarction, stroke or transient isch-
emic attack, claudication, unstable angina, carotid endarterectomy, coronary artery bypass 
graft, peripheral arterial bypass or angioplasty.13,22 Apart from standard clinical work-up for 
expected acute PE, the included patients were not systematically screened for occult cancer 
in neither of the two participating hospitals. Thus, the patients in whom cancer was detected 
had developed symptomatic malignant disease or the cancer was an accidental finding dur-
ing regular clinical care. 
Statistical analysis
All patients were followed from the index event to the date of death or July 1st 2008, 
whichever came first. The Kaplan-Meier life table method was used to estimate the event 
free survival for all individual study endpoints and for the combined endpoint of adverse 
outcome in patients with unprovoked, provoked and without PE. For this latter analysis, the 
adverse event that occurred first was accounted for. The Log-Rank test was used for compar-
ing the three study groups for statistical differences. A Cox proportional hazard model was 
used to calculate hazard ratios (HR) for adverse clinical events. HRs were adjusted for age, sex 
and in addition all further relevant patient demographics; recurrent VTE and CTEPH for initial 
treatment; malignancy for active smoking; cardiovascular events for active smoking, diabetes 
and use of anti-platelet, lipid-lowering or blood pressure-lowering medication; mortality for 
left sided heart failure, COPD and active malignancy; and overall adverse events for all above 




The diagnosis of acute PE had been established in 877 patients between January 1st 2001 
and July 1st 2007 in the two participating hospitals. Eleven patients were excluded because 
of geographical inaccessibility (1.3%), leaving 866 patients for analysis. In addition, 334 
patients without PE were included. The final diagnosis in the 334 patients in whom acute 
PE was suspected but ruled out was infectious disease in 84 (25%), non infectious or malig-
nancy associated pulmonary disease in 43 (13%), complications of an active malignancy in 
47 (14%), musculoskeletal disease in 37 patients (11%), cardiovascular disease in 33 (9.9%), 
gastrointestinal disease in 17 (5.1%) and other/unknown in 73 patients (22%). General 
characteristics of the study patients are presented in Table 1: the patients without PE were 
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significantly younger than the patients with provoked and unprovoked PE (48 ±17 vs. 55 ±18 
and 59 ±17 years respectively). In addition, the fraction of male patients was lowest in the 
patients without PE (37% vs. 47% and 48% respectively). Further, the presence of comorbidity 
and cardiovascular risk factors was similar between the three study groups, except for active 
malignancy, which was most frequently present in patients with provoked PE. Lastly, the 
patients with unprovoked and provoked PE received comparable anticoagulant treatment. 
The median follow-up period for the complete study population was 3.3 years.
Risk for recurrent VTE and CTEPH
Symptomatic recurrent VTE was diagnosed in 64 (21%) patients with unprovoked PE and 
in 54 (9.7%) patients with provoked PE (Table 2, Figure 1) during follow-up. The adjusted 
HR for recurrent VTE was increased for patients with unprovoked versus provoked PE (2.1, 
95% CI 1.3- 3.1) and versus patients without PE (10, 95% CI 4.9-28). Patients with provoked 
PE had higher risk on recurrences than the control patients as well (adjusted HR 6.0, 95% 
CI 2.8-13). Recurrent PE was fatal in 22 of the 118 patients initially diagnosed with PE (19%, 
95% CI 12-27%), and in 1 of the 4 (25%, 95% CI 0.06-81%) VTE diagnoses in the control pa-
tients. Recurrences within the first 3 weeks after the index diagnosis were associated with 
significantly higher mortality (Odds Ratio 7.9, 95% CI 1.2-51). CTEPH was only diagnosed in 
four patients after unprovoked acute PE (cumulative incidence 1.5%), and not in the patients 
with provoked PE or without PE (Table 2). The four patients diagnosed with CTEPH were all in 
stable clinical condition at the end of the follow-up period.







Age at index event (years ±SD) 59±17*¶ 55±18¶ 48±17
Male sex (n, %) 149 (48)¶ 261 (47)¶ 123 (37)
Initial treatment† 
 Low molecular/unfractioned heparin (n, %) 285 (93) 523 (94) NA
 Thrombolysis (n, %) 14 (4.5) 24 (4.3) NA
Surgery, VCF or both (n, %) 9 (2.9) 11 (2.0) NA
COPD† (n, %) 26 (8.4) 57 (10) 33 (9.9)
Left sided heart failure† (n, %) 16 (5.2) 26 (4.7) 11 (3.3)
Active malignancy† (n, %) 0 (0)*¶ 201 (36)¶ 46 (14)
Diabetes† (n, %) 18 (5.8) 27 (4.8) 17 (5.1)
Active smoking† (n, %) 102 (33) 172 (31) 110 (33)
Anti-platelet/lipid-lowering/blood pressure-lowering 
medication‡ (n, %)
151 (49) 240 (43) 147 (44)
PE=Pulmonary embolism, SD=standard deviation, n=number, VCF=vena cava filter; COPD=chronic obstructive 
pulmonary disease; NA=not applicable; †at index event; ‡at hospital discharge after index event; *p<0.05 vs. 
provoked PE; ¶p<0.05 vs. no PE. Continuous parameters were compared using ANOVA with Bonferroni post hoc 
testing; bivariate variables were compared by the Chi-Square test.
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A pooled survival analysis of adverse events after pulmonary embolism 
Risk for malignancy and arterial cardiovascular events
The risk for cancer was higher for the patients after unprovoked PE than for the patients with 
provoked (adjusted HR 4.4, 95% CI 2.0-10) and without PE (adjusted HR 2.5, 95% CI 1.1-2.7; 
Table 2, Figure 1). There was no difference in the rate of newly diagnosed malignancies be-
tween patients with provoked and without PE (adjusted HR 0.78, 95% CI 0.26-1.4). In 27 of the 
31 patients with PE (87%, 95% CI 70-96%) who were diagnosed with cancer, this malignancy 
was detected within the first year after the index PE. Patients with unprovoked PE suffered 
severe cardiovascular disease two to three times more often than the patients from the other 
two study cohorts (adjusted HR 2.6, 95% CI 1.5-3.8 and 2.4, 1.2-3.7 respectively; Table 2, Fig-
ure 1). Patients with PE, who suffered arterial cardiovascular events or were diagnosed with 
cancer had case fatality rates of 14% (95% CI 7.0-24) and 19% (95% CI 7.5-37) respectively. 
Risk for mortality
In total, 259 (30%) patients with PE died, mainly as a result of a malignancy (110 patients, 
13%). Furthermore, 67 (7.7%) patients died of (recurrent) PE, 6 (0.69%) because of severe 
bleeding from anticoagulant therapy, 30 (3.5%) of cardiovascular disease, 11 (1.3%) of non-
malignant pulmonary disease and 35 (4.2%) of other causes. Twenty-nine patients without PE 
died during the study period (8.7%): 1 of acute PE (0.30%), 1 of myocardial infarction (0.30%), 
Table 3: Yearly overall event free survival for patients with unprovoked, provoked and without acute PE. 
Follow-up 
period Unprovoked PE (n=308) Provoked PE (n=558) Overall PE 
(n=866)
No PE (n=334)
NLFA Event free 
survival§ (±SE)




NLFA Event free survival§ 
(±SE)
1 year 212 0.70±0.026 379 0.68±0.020 0.69±0.016 298 0.94±0.014
2 years 151 0.59±0.028 280 0.61±0.021 0.60±0.017 275 0.90±0.017
3 years 108 0.52±0.030 195 0.56±0.022 0.54±0.018 265 0.87±0.019
4 years 78 0.48±0.031 122 0.54±0.023 0.51±0.018 203 0.84±0.021
5 years 52 0.45±0.032 76 0.50±0.025 0.48±0.019 78 0.80±0.024
6 years 31 0.44±0.034 37 0.48±0.027 0.46±0.021 26 0.77±0.038
7 years 14 0.42±0.038 16 0.47±0.028 0.45±0.024 9 0.76±0.041
PE=pulmonary embolism, SE=standard error, n=number, NLFA=number left for analysis. §Estimated by Kaplan-
Meier life table method.
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4 of non-ischemic heart diseases (1.2%), 3 of non-malignant pulmonary disease (1.2%), 12 of 
malignancies (3.6%) and 8 by other causes (2.4%). Risk for overall mortality in patients after 
unprovoked PE was lower than in patients after provoked PE (adjusted HR 0.59, 95% CI 0.43-
0.82; Table 2, Figure 1). Intriguingly, the patients with unprovoked PE who by definition did 
not suffer from active malignancies at time of the index event, were at higher risk for dying 
than the non-cancer patients with provoked PE (adjusted HR 1.8, 95% CI 1.3-2.5). Patients 
with unprovoked as well as with provoked PE had higher risks for death than the control 
patients (adjusted HR 1.4, 95% CI 1.1-1.8 and 2.9, 95% CI 2.1-3.8 respectively). 
Risk for overall adverse outcome
The prognostic differences between patients with unprovoked and provoked PE disappeared 
after combining all adverse events to one pooled endpoint of adverse outcome (adjusted 
HR 0.98, 95% CI 0.82-1.1; Table 2, Figure 1). Nonetheless, both groups had significantly worse 
prognosis than the control patients without PE (adjusted HR 2.6, 95% CI 1.9-3.6 and 2.9, 2.1-
3.8 respectively). Importantly, the fraction of PE patients without any event after 1 year was 
only 69% and decreased to 60% after 2 years and 50% after 4 years (Table 3, Figure 1). These 
numbers were applicable to both patients with unprovoked as well as with provoked PE. 
The patients without PE had significant higher event free survival with 84% of the patients 
surviving without any of the adverse events after a follow-up period of 4 years.
Discussion
We aimed to evaluate the long term overall prognosis of patients after acute PE. Two impor-
tant conclusions can be drawn from this analysis. First, we have demonstrated that after 1 
year of follow-up, only 70% of the patients are free of adverse outcome and notably, after 
a period of 4 years, half of the patients developed one or more serious clinical complica-
tions. A control cohort consisting of patients in whom PE was suspected but ruled out had 
significantly higher event free survival. Second, although risks for the occurrence of specific 
adverse events differed significantly between patients with unprovoked and provoked PE, 
the risk of the combined endpoint of adverse outcome was similar between the two patient 
groups, both higher than for the control patients without PE.
The importance of our findings is underlined by the complication specific prognosis, 
which is poor for all adverse events studied in this analysis. First, the index PE itself had a 
mortality rate of 5.2%, which compares well to the existing literature.1-4 Second, recurrent 
VTE was diagnosed in 118 patients. Previous studies have shown that thrombotic recurrences 
are associated with increased mortality.5,7 The case fatality rate in our study was 19% in the 
complete study period and even 60% within the first 3 weeks after the index diagnosis. This 3 
weeks mortality rate is comparable to the range of 51-79% that was reported in earlier stud-
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ies.5,7,23 In addition, according to the latest ACCP guidelines, recurrent VTE should be treated 
with long term anticoagulant therapy (Grade 1A), which is associated with an increased risk 
of often severe bleeding complications.20 Third, cancer diagnosed at the same time as or 
shortly after the diagnosis of VTE is a bad prognostic sign, as this is associated with more 
advanced stages of cancer and a poor prognosis.18 Sørensen et al have shown that patients 
in whom cancer was diagnosed within 1 year after the diagnosis of VTE had an increased risk 
of distant metastasis at the time of diagnosis and a relatively low rate of survival compared 
to patients with cancer without a history of VTE.18 In our population, cancer diagnosed after 
the index PE proved to be fatal in 19% of the cases within the follow-up period. The associa-
tion between unprovoked PE and the subsequent development of clinically overt cancer is 
most likely explained by the fact that these cancers are already present at the time of, and 
may even be causally related to the PE, although not yet detected.17 Fourth, although the 
exact mechanism underlying the association between arterial cardiovascular events and VTE 
is unknown, evidence exists that both diseases are closely linked.10,13 The observation that 
control patients without PE and patients with provoked PE have the same risk for arterial 
cardiovascular events, which is significantly lower than for patients after unprovoked PE, 
supports the hypothesis that a shared but yet unidentified mechanism causes events in both 
the venous and the arterial system.13
Arterial events such as myocardial infarction or stroke have great implications for the 
patients’ health and lead to high morbidity and mortality rates and decreased quality of life.15 
Lastly, four patients were diagnosed with CTEPH (cumulative incidence in patients with un-
provoked PE 1.5%). This percentage is relatively low compared to some recent studies report-
ing incidences of 3.8% and even 8.8% in patients after PE.12,16 This discrepancy might very well 
be explained by different selection criteria than in previous studies, or by underdiagnosis of 
CTEPH in our cohort, although the included patients with PE were systematically screened 
for the presence of pulmonary hypertension.14 Even though none of our four patients with 
CTEPH died during the study period, it has previously been shown in larger cohorts that the 
prognosis of patients with CTEPH is rather poor, unless a successful pulmonary endarterec-
tomy is achievable.6 
Thus, we have combined four very serious complications of PE as well as all-cause mortality 
in this analysis. The pooled endpoint of adverse outcome was reached by 50% or more of the 
patients with PE after 4 years of follow-up, which is significantly more than for the control 
patients. Remarkably, this overall prognosis is comparable for patients with unprovoked and 
patients with provoked PE. This latter observation was mainly driven by the malignancy re-
lated high mortality rates in the patients with provoked PE. Further analysis showed that pa-
tients with unprovoked PE have in fact the highest risk on non-malignancy related mortality 
and all the other included endpoints. These findings emphasize that acute PE is an important 
clinical problem with poor prognosis for short and long term survival and the occurrence of 
serious thrombotic or non-thrombotic adverse events. 
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Many risk stratification and screening strategies including intensified or prolonged anti-
thrombotic therapy regimes to identify and treat patients with high risk for PE-related mor-
tality, recurrent VTE or detection of cancer have been proposed, but all remain insufficient or 
controversial.20,24-27 An earlier study concluded that treatment of heparin and anticoagulants 
is not enough for all PE patients.28 Our results, although almost 30 years later, confirm this 
conclusion and once more emphasize the poor overall prognosis of patients with acute PE. 
In current clinical practice and despite the increased risk for serious clinical complications, 
patients with a first episode of acute PE stop their anticoagulant therapy usually after 3-6 
months.20 From then on, they are usually no longer subject to clinical supervision by a medical 
specialist. Importantly, by lack of scientific based evidence and proven cost-efficacy, standard 
screening for classic cardiovascular risk factors, hidden cancer or CTEPH is at this moment 
not part of routine clinical work-up of patients with PE. Our results underline the importance 
of close clinical surveillance in the first months after PE, especially in those patients with 
unprovoked PE, to evaluate the basic risks for future adverse events and in addition, treat 
patients accordingly. Therefore, future outcome studies should focus on 1) better individual 
assessment of the risk for recurrent venous thromboembolism and CTEPH to enable the phy-
sician to identify those patients who could benefit from prolonged anticoagulant therapy or 
specific screening for pulmonary hypertension; 2) effectiveness of cardiovascular risk factor 
evaluation and proper treatment measures to prevent arterial cardiovascular events; and 
3) effect of specific screening programs for underlying malignancies, to achieve very early 
identification of hidden malignancies thereby potentially improving the patients’ prognosis.
Our study has strengths and limitations. Our findings are likely to be generalizable to most 
patients with PE since we have included all consecutive patients diagnosed with this disease 
in an academic and non-academic teaching hospital independently of their clinical condition 
or comorbidity. Even though our study endpoints are severe clinical events that are likely to 
be recorded in detail, we have additionally verified the accuracy and completeness of the 
data from the medical charts with the surviving patients. Only 11 patients with PE (1.3%) 
who could not be reached due to geographical inaccessibility, were excluded. Furthermore, 
our findings are in accordance with the extensive literature on this subject, although we are 
the first to combine all adverse events into one pooled endpoint. We acknowledge that we 
were not able to report on all bleeding events, which are important complications in the 
clinical course of acute PE. Nonetheless, the adverse effect of bleeding is often transient and 
the period at risk is limited to the first 6 months after diagnosis in the majority of patients. 
Moreover, the most severe bleedings that resulted in mortality could in fact be accounted for. 
We conclude that acute PE remains a very serious clinical condition with high mortality 
and high risk on PE associated severe complications. Remarkably, there was no difference in 
the pooled risk for adverse outcome of patients with unprovoked and provoked PE, although 
the risk on all separate endpoints except for overall mortality was markedly higher for the 
patients with unprovoked PE. Physicians should be well aware of the fact that in 4 years time, 
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half of the patients diagnosed with acute PE has died or is diagnosed with cancer, recurrent 
VTE, CTEPH or arterial cardiovascular disease. The challenge of future trials remains to enable 
the treating physician to use accurate prediction tools for adjusting treatment regimes and 
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Current knowledge on diagnostic management and treatment of patients with acute 
pulmonary embolism (PE) is partly derived from outcome studies including patients from 
university hospitals alone. It is debatable whether these data are applicable to patients in 
non-university hospitals. The aim of this study was to compare baseline characteristics and 
clinical outcome of patients with PE treated in university hospitals versus patients treated in 
non-university hospitals.
Methods
Post-hoc analysis on data derived from Christopher study, a prospective multicenter man-
agement study.
Results 
A total of 399 (59%) patients with PE presented to a university hospital and 275 (41%) to a 
non-university teaching hospital. The characteristics of patients from the university and non-
university hospitals were different with respect to female ratio (46% vs. 56%, Odds Ratio [OR] 
0.65, 95% confidence interval [CI] 0.47-0.88), outpatient ratio (73% vs. 84%, OR 0.53, 95%CI 
0.36-0.79), presence of immobilization (37% vs. 23%, OR 2.0, 95%CI 1.4-2.8) and the presence 
of active malignancy (19% vs. 12%, OR 1.6, 95%CI 1.1-2.5). Risk on venous thromboembolic 
recurrence (3.3% vs. 2.6% OR 1.3, 95%CI 0.50-3.3) and mortality (9.0% vs 6.9% OR 1.3, 95%CI 
0.75-2.4) were higher for patients in university than in non-university hospitals. Bleedings 
occurred twice more often in patients from university hospitals (4.3% vs 2.2% OR 2.0, 95%CI 
0.77-5.1).
Conclusion
Physicians should be aware of differences in patient characteristics and outcome between 
university and non-university hospitals when interpreting results from large clinical trials and 
applying these to their everyday medical practice.
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Introduction
Current knowledge regarding diagnostic management and treatment of patients with acute 
pulmonary embolism (PE) is mainly derived from large outcome studies including patients 
from university and non-university hospitals or university hospitals alone.1-4 A common per-
ception of university hospitals is that they treat more severely ill patients than non-university 
hospitals.5 Therefore, it must be debated whether data on the diagnostic management and 
treatment of patients with acute PE derived from university hospitals are relevant and appli-
cable to everyday patient care in non-university hospitals, and vice-versa. We hypothesized 
that patients from university hospitals would be a population with more comorbidity than 
in non-university hospitals. Accordingly, we investigated differences between baseline risk 
factors predicting adverse clinical outcome (e.g. higher age, immobilization, cancer and 
cardiopulmonary comorbidity) in patients with established acute PE in university and non-
university hospitals. In addition, the clinical outcome of these patient groups was compared. 
Methods
We performed a post-hoc analysis on data obtained from a large multicenter prospective 
cohort follow-up study.2 In this study, executed from November 2002 until September 2004, 
consecutive hemodynamic stable patients with computed tomography proven acute PE were 
followed for a period of 3 months to document the occurrence of recurrent symptomatic 
venous thromboembolic events. All patients were treated according to the previously fol-
lowed guidelines.6 Furthermore, all patients were treated as inpatients and hemodynamically 
instable patients were excluded from the study. Therefore, no patient was treated with fibri-
nolytic drugs or vena cava filter. Secondary endpoints were all-cause mortality and bleeding 
complications. Follow-up consisted of a hospital visit or telephone interview with the patient 
after 3 months. Patients were instructed to contact the study center immediately in case of 
complaints suggestive of PE, deep vein thrombosis (DVT) or bleeding. In case of clinically 
suspected DVT, PE or bleeding objective tests were performed to confirm the diagnosis. 
Symptomatic recurrent VTE was considered to have occurred if recurrent PE or DVT were 
documented objectively, or if there was a death in which PE could not be confidently ruled 
out as a contributing cause. The objective criterion for the diagnosis of recurrent PE was a new 
intraluminal filling defect on spiral CT or pulmonary angiography, cut-off of contrast material 
in a vessel > 2.5 mm in diameter on pulmonary angiography, a new perfusion defect involving 
at least 75% of a segment, with corresponding normal ventilation (i.e. a high probability lung 
scan), a new non-diagnostic lung scan accompanied by documentation of DVT by ultraso-
nography or venography, or confirmation of a new PE at autopsy. The objective criterion of a 
new DVT was a new, non-compressible venous segment or a substantial increase (≥ 4 mm) in 
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the diameter of the thrombus during full compression in a previously abnormal segment on 
ultrasonography or a new intraluminal filling defect on venography. Mortality was defined as 
death due to recurrent PE (fatal PE), fatal bleeding, cancer, or another established diagnosis. 
Information about the cause of death was obtained from autopsy reports or from a clinical 
report. Hemorrhagic complications were the composite of major bleeding and clinically 
relevant bleeding. Major bleeding was defined as fatal bleeding, and/or symptomatic bleed-
ing in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, 
intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding 
causing a fall in hemoglobin level of ≥ 20 g/L (1.24 mmol/L), or leading to transfusion of ≥ 2 
U of whole blood or red cells. Bleeding was considered clinically relevant when the episode 
did not qualify as a major bleeding but included one of the following: epistaxis requiring 
intervention, formation of a large hematoma visible on the skin or spontaneous macroscopic 
hematuria.7  All patients were treated with therapeutic doses of unfractionated or low mo-
lecular weight heparin followed by vitamin K antagonist for a period of at least 6 months. 
Patients diagnosed as outpatients as well as inpatients were eligible. The study was executed 
in 12 hospitals in the Netherlands, of which five were university hospitals. Non-university 
hospitals differed in size from 330 to 1386 patient beds and university hospitals from 715 to 
1100 patient beds. All participating centers had comparable services including emergency 
units, intensive care units and 24-hour access to a CT scan. A total of 673 patients with acute 
PE completed 3 months follow-up with one patient lost to follow-up (0.15%).
Results
The baseline characteristics of the included patients are shown in Table 1. A total of 399 (59%) 
patients attended a university hospital and 275 (41%) a non-university teaching hospital. 
The characteristics of patients from the university and non-university hospitals were different 
with respect to female ratio (46% vs. 56%, Odds Ratio [OR] 0.65, 95% confidence interval [CI] 
0.47-0.88), outpatient ratio (73% vs. 84%, OR 0.53, 95% CI 0.36-0.79), presence of immobiliza-
tion (37% vs. 23%, OR 2.0, 95% CI 1.4-2.8) and the presence of active malignancy (19% vs. 
12%, OR 1.6, 95% CI 1.1-2.5). The rates of adverse clinical events are presented in Table 2. 
Overall 55 patients died; of these, 11 patients died because of fatal recurrent PE and two 
died because of fatal hemorrhage. The cause of death in the remaining patients was mainly 
malignancy or cardiovascular disease. The time of death ranged from 1 to 90 days, with a 
median of 22 days. Risk of venous thromboembolic recurrence (3.3% vs. 2.6% OR 1.3, 95% 
CI 0.50-3.3) and mortality (9.0% vs. 6.9% OR 1.3, 95% CI 0.75-2.4) was higher for patients in 
university than in non-university hospitals. Furthermore, bleeding occurred in 23 patients, 
and was fatal in two of these. Both fatal bleeding events occurred out of hospital, while seven 
of the eight non-fatal major bleedings occurred in the hospital and 7 of 13 clinically relevant 
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bleedings occurred in the hospital. Hemorrhagic complications occurred twice more often 
in patients from university hospitals (4.3% vs. 2.2% OR 2.0, 95% CI 0.77-5.1). These bleeding 
complications were strongly associated with the baseline presence of active malignancy (OR 
3.4, 95% CI 1.5-7.9). 







Age (years) 56± 18 59±18 NS
Female gender 183 (46) 156 (56) 0.65 (0.47-0.88)
Duration of complaints (days) 5.9±11 6.4±10 NS
Outpatients 294 (73) 231 (84) 0.53 (0.36-0.79)
Risk factors for VTE
Paralysis 23 (5.8) 15 (5.5) NS
Immobilization 151 (37) 65 (23) 2.0 (1.4-2.8)
Recent surgery 33 (8.3) 34 (12) NS
History of VTE 69 (17) 48 (17) NS
Heart failure 26 (6.5) 14 (5.1) NS
COPD 34 (8.5) 28 (10) NS
Active malignancy 89 (19) 41 (12) 1.6 (1.1-2.5)
Clinical findings
Hemoptysis 37 (9.3) 19 (6.9) NS
Tachycardia 143 (35) 104 (37) NS
Categorical data are displayed as No (%). Numerical data are displayed as means ± standard deviation. VTE= 
venous thromboembolism, COPD = chronic obstructive pulmonary disease, OR = Odds Ratio
Table 2. Adverse clinical outcome in a three months follow-up period 



























All cause mortality 36 (9.0) 19 (6.9)
Data are displayed as No (%). 




Our data demonstrate that patients with acute PE presenting to university hospitals are dif-
ferent from patients presenting to non-university hospitals regarding gender, proportion of 
outpatients and malignancy. Especially the latter two are established risk factors for adverse 
events and mortality in the first 3 months following acute PE.8 To our best knowledge, there 
were no different characteristics between the hospitals other than being a university hospital, 
which could have biased these study observations. According to our hypothesis we identified 
differences in baseline characteristics and observed a higher rate of adverse clinical events in 
patients from university hospitals than in patients from non-university hospitals. Of note, we 
found a significant association between bleeding and malignant comorbidity. This associa-
tion has been described previously and thus underlines the validity of our study results.9 Of 
note, correlations between additional patient demographics were not studied. A limitation 
of our study is that although we have performed a post hoc analysis of a reasonable large 
patient cohort, the study might have included too few patients to detect a significant differ-
ence between the patient cohorts.
In summary, we have identified important differences in demographics, comorbidity and 
clinical outcome between patients diagnosed with PE in university and in non-university 
hospitals. Physicians should be aware of these differences when interpreting results from 
large clinical trials and applying these to their everyday medical practice.
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General discussion and summary
The aims of this thesis were to investigate the efficacy and safety of outpatient treatment of 
patients with pulmonary embolism (PE) and to identify the best method for selection of PE 
patients for outpatient treatment. Therefore, we performed the Hestia study and compared 
the selection of patients with the Hestia criteria to other methods for risk stratification, for 
example the simplified Pulmonary Embolism Severity Index and the method described in the 
European Society of Cardiology guidelines. Chapter 1 provides a general introduction to the 
history of treatment of patients with PE and an overview of risk stratification methods.
A recent systematic review on outpatient treatment in PE patients concluded that outpa-
tient treatment could not be implemented in clinical practice yet, because only a few small 
observational studies could be included. High quality evidence on the safety of outpatient 
PE treatment was lacking.1 In recent years large studies have been published on the subject, 
including the Hestia study.2-4 The results of the large, multicenter Hestia study are described 
in chapter 2. This study was performed in 12 Dutch hospitals from 2008 to 2010. Patients 
with acute and symptomatic PE were screened for eligibility for outpatient treatment with 
the Hestia criteria: 11 clinical criteria based on signs and symptoms. We concluded that out-
patient treatment following the Hestia criteria is safe, because patients had a low incidence 
of recurrent venous thromboembolism (VTE) of 2.0% (95% confidence interval (CI) 0.8-4.3), 
a low incidence of major bleeding of 0.7% (95% CI 0.08-2.4) and a low incidence of all-cause 
mortality of 1.0% (95% CI 0.2-2.9). None of the patients treated at home died of fatal PE. These 
favorable clinical outcomes in patients treated as outpatients are contrasted by the more 
severe clinical outcomes in patients selected for hospital treatment by the Hestia criteria, as 
discussed in chapter 3. Patients treated in-hospital had marked higher incidences of recur-
rent VTE of 3.9%, major bleeding of 4.8% and all-cause mortality of 9.6%. Five patients treated 
as inpatients died of PE-related causes in contrast to none of the patients treated at home. 
Therefore, we concluded that the Hestia criteria can be used to discriminate PE patients with 
low risk for adverse clinical outcome from patients with high risk for adverse clinical outcome. 
Low-risk patients with PE can be safely treated at home.
Because a few large studies investigating outpatient treatment of patients with PE had 
been published recently, we performed a meta-analysis on this subject (chapter 4). In this 
meta-analysis we pooled incidences of recurrent VTE, major bleeding and all-cause mortal-
ity of three groups of patients: patients treated as outpatients, patients admitted initially 
to the hospital, but discharged early within 3 days and patients treated in the hospital for 3 
days or more. Patients treated as outpatients had equally low pooled incidences of recurrent 
VTE 1.7%, major bleeding 1.0% and all-cause mortality 1.9% as patients discharged early or 
treated as inpatients. We concluded that home treatment or early discharge of selected low-
risk patients with acute PE is as safe as inpatient treatment.
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Besides the Hestia criteria, other methods for risk stratification in outpatient PE treatment 
have been described: methods based on clinical signs and symptoms5,6, laboratory values7 
and imaging modalities.8 In chapter 5 the performance of the Hestia criteria was compared to 
the performance of the simplified Pulmonary Embolism Severity Index (sPESI) for prediction 
of 30-day mortality.9 Both methods had a good performance in selecting PE patients with low 
risk for 30-day mortality; the negative predictive value for the Hestia criteria was 99% and for 
the sPESI 100%. The advantages of the use of the Hestia criteria are that these criteria can 
be implemented in clinical practice without modifications, in contrast to the sPESI. With the 
Hestia criteria more than 50% of PE patients can be selected for outpatient treatment, which 
is high compared to the sPESI. Although both the Hestia criteria and the sPESI had good 
test characteristics in predicting 30-day mortality, according to the Hestia criteria 20-30% of 
patients with cancer, cardiopulmonary co-morbidity or elderly patients can be safely treated 
at home. These patients would have been excluded from outpatient treatment by the sPESI.  
In chapter 6 we compared the performance of the Hestia criteria to the selection method 
advised by the European Society of Cardiology (ESC). The ESC method combined hemody-
namic status (blood pressure and heart frequency) with right ventricular (RV) function to 
assess whether patients were eligible for outpatient treatment. Adverse events occurred 
in 22 patients (4.5%) treated in the hospital versus none in the patients treated at home 
(p<0.001). Sensitivity and negative predictive value for adverse outcome were 100% for the 
Hestia criteria and 83% and 98% for the ESC criteria, respectively. Of the patients treated at 
home according to the Hestia criteria, 34% could not have been treated at home according 
to the ESC criteria because they had RV dysfunction. When this group of patients with RV dys-
function was treated at home in the Hestia study no adverse events happened. In conclusion 
clinical criteria, like the Hestia criteria, could be helpful in selecting patients, including those 
with RV dysfunction, who have low risk for adverse clinical outcome and could be candidates 
for outpatient treatment.
Elevated NT-proBNP is a known risk factor for adverse outcome after PE.10 One study 
previously selected patients with a low NT-proBNP and treated them at home safely.7 We 
hypothesized that repeated measurements of NT-proBNP could potentially select a larger 
proportion of patients with PE for early discharge from the hospital. The results are presented 
in chapter 7. We demonstrated that repeated NT-proBNP testing within 48 hours after pre-
sentation with PE can identify 20% extra patients with PE as low risk than when using a single 
measurement at day 1.
Patients with PE without a provoking risk factor have a higher risk for various types of 
adverse clinical outcome, including non-malignancy related mortality, newly diagnosed 
malignancies and recurrent VTE, than patients with provoked PE. Importantly, chapter 8 
demonstrated that the fraction of all patients without clinical adverse events 1 year after 
PE was only 70% and decreased to fewer than 60% after 2 years and fewer than 50% after 4 
years, whereas this latter was 84% for the control patients without PE. 
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In chapter 9 an additional risk factor for adverse outcome after PE is described. Patients ad-
mitted to university hospitals had higher risks on venous thromboembolic recurrence (3.3% 
vs. 2.6%; odds ratio (OR) 1.3, 95% CI 0.50-3.3) and mortality (9.0% vs. 6.9% OR 1.3, 95% CI 
0.75-2.4) than patients in non-university hospitals. Furthermore, hemorrhagic complications 
occurred twice more often in patients from university hospitals (4.3% vs. 2.2% OR 2.0, 95% CI 
0.77-5.1). These bleeding complications were strongly associated with the baseline presence 
of active malignancy (OR 3.4, 95% CI 1.5-7.9). Our data demonstrate that patients with acute 
PE presenting to university hospitals are different from patients presenting to non-university 
hospitals regarding baseline characteristics (gender, proportion of outpatients and malig-
nancy) and clinical outcome. Physicians should be aware of these differences when interpret-
ing results from large clinical trials and applying these to their everyday medical practice.     
Future perspectives
Evidence on the safety of outpatient treatment of patients with PE is accumulating. The 
recent American College of Chest Physicians guidelines give a grade 2B recommendation on 
the safety of early discharge of selected PE patients.11 Before outpatient treatment of patients 
with PE will be graded with an 1A recommendation, more high quality evidence is needed. 
As suggested in this thesis, risk stratification of normotensive patients with PE can be based 
on clinical criteria, biomarkers or measurements of RV dysfunction. Current evidence from 
large multicenter studies, including the Hestia study, suggests that patients with a low risk for 
adverse events can be treated on outpatient basis. However, it is yet to be determined which 
method of risk stratification most safely selects patients for outpatient treatment. Therefore, 
trials have to be performed in which different selection methods for outpatient treatment 
will be compared, preferably in a randomized way.
Another important change in treatment of patients with PE will be the introduction of 
the new oral anticoagulants (NOACs), for example the factor Xa and thrombine inhibitors. 
Clinical trials on the efficacy and safety of these drugs in treatment of PE patients are on-
going. Introduction of NOACs will potentially simplify the outpatient treatment of patients 
with PE, because these medications do not need frequent laboratory monitoring. However, 
before NOACs can be used in the outpatient treatment of patients with PE, adequate care 
has to be guaranteed, especially in the first weeks. In the future, prospective trials have to be 
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De doelen van dit proefschrift waren om de veiligheid en effectiviteit van thuisbehande-
ling van patiënten met longembolie te onderzoeken en de beste methode te identificeren 
waarmee patiënten voor thuisbehandeling geselecteerd kunnen worden. Om dit te bereiken 
hebben we de Hestia Studie uitgevoerd en de criteria die gebruikt zijn in de Hestia studie 
(Hestia criteria) vergeleken met andere methoden voor risicoselectie die beschikbaar zijn, 
bijvoorbeeld de gesimplificeerde Pulmonary Embolism Severity Index (sPESI) en de methode 
zoals beschreven door de European Society of Cardiology. Hoofdstuk 1 geeft de geschiede-
nis weer van de behandeling van patiënten met longembolie en dient als een algemene 
introductie. Tevens wordt een overzicht gegeven van de beschikbare methoden voor risico-
stratificatie.
In een recent verschenen overzichtsartikel over thuisbehandeling van patiënten met long-
embolie werd geconcludeerd dat thuisbehandeling nog niet veilig genoeg was voor imple-
mentatie in de klinische praktijk, omdat slechts kleine observationele studies beschikbaar 
waren en kwalitatief hoogstaand bewijs ontbrak. In de afgelopen jaren zijn enkele grote 
studies verschenen die de thuisbehandeling van longembolie onderzochten, waaronder 
de Hestia studie. De resultaten van de Hestia studie zijn beschreven in hoofdstuk 2. Deze 
grote multicenter studie is van 2008 tot 2010 uitgevoerd in 12 Nederlandse ziekenhuizen. 
Patiënten met acute en symptomatische longembolie zijn gescreend met de Hestia criteria 
(11 klinische criteria) om te bepalen of ze in aanmerking kwamen voor thuisbehandeling. 
Onze conclusie was dat patiënten met longembolie veilig thuis behandeld konden worden 
als ze geselecteerd waren met de Hestia criteria, omdat de patiënten uit de Hestia studie 
een laag percentage recidief veneuze trombo-embolieën (VTE) van 2.0% (95% CI 0.8-4.3), 
een laag percentage majeure bloedingen van 0.7% (95% CI 0.08-2.4) en een lage mortaliteit 
van 1.0% (95% CI 0.2-2.9) hadden. Geen van de patiënten die thuis zijn behandeld overleden 
aan fatale longembolie. Deze gunstige klinische uitkomsten van thuisbehandelde patiënten 
staan in contrast met de ernstiger klinische uitkomsten van patiënten die geselecteerd waren 
voor behandeling in het ziekenhuis, zoals besproken wordt in hoofdstuk 3. Patiënten die 
geselecteerd waren voor behandeling in het ziekenhuis hadden hogere incidenties van 
recidief VTE van 3.9%, majeure bloeding van 4.8% en mortaliteit van 9.6%. Vijf patiënten die 
behandeld waren in het ziekenhuis zijn overleden aan longembolie gerelateerde oorzaken 
in tegenstelling tot geen van de patiënten die thuis behandeld zijn. Hierdoor hebben we 
geconcludeerd dat de Hestia criteria een goed onderscheid kunnen maken tussen patiënten 
met een laag en hoog risico op negatieve klinische uitkomsten. De longemboliepatiënten 
met een laag risico op negatieve klinische uitkomsten kunnen thuis behandeld worden.
Omdat recent een aantal grote studies naar thuisbehandeling van patiënten met long-
embolie is verschenen, hebben we een meta-analyse uitgevoerd (hoofdstuk 4). In deze 
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meta-analyse hebben we gewogen incidenties van recidief VTE, majeure bloeding en 
mortaliteit bepaald in drie groepen: patiënten die volledig thuis behandeld waren, patiënten 
die initieel in het ziekenhuis behandeld waren, maar binnen drie dagen naar huis ontslagen 
zijn en patiënten die drie dagen of meer in het ziekenhuis behandeld waren. Patiënten die 
thuis behandeld waren, hadden vergelijkbaar lage incidenties van recidief VTE 1.7%, majeure 
bloeding 1.0% en mortaliteit 1.9% als patiënten die vervroegd ontslagen waren en patiënten 
die volledig in het ziekenhuis behandeld waren. Onze conclusie luidde dat thuisbehandeling 
of vervroegd ontslag uit het ziekenhuis van geselecteerde laagrisico patiënten met longem-
bolie tenminste even veilig is als behandeling van patiënten in het ziekenhuis.  
In de Hestia studie hebben we 11 klinische criteria, de zogenaamde Hestia criteria, gebruikt 
om patiënten met longembolie te selecteren voor thuisbehandeling. Er zijn ook andere 
methoden voor risicostratificatie beschreven, zoals methoden die gebruik maken van klini-
sche symptomen en bevindingen, laboratoriumbepalingen of beeldvormende technieken. 
In hoofdstuk 5 hebben we de Hestia criteria vergeleken met de gesimplificeerde PESI wat 
betreft het voorspellend vermogen voor mortaliteit binnen 30 dagen. Beide methoden voor 
risicostratificatie presteerden goed in het selecteren van laagrisico patiënten; de negatief 
voorspellende waarde was 99% voor de Hestia criteria en 100% voor de sPESI. Echter, bij 
het gebruik van de Hestia criteria kwam een kwart meer patiënten in aanmerking voor 
thuisbehandeling ten opzichte van de sPESI. Een ander voordeel van het gebruik van de 
Hestia criteria was dat deze criteria in de klinische praktijk kunnen worden geïmplementeerd 
zonder aanpassingen, in tegenstelling tot de sPESI. 
In hoofdstuk 6 hebben we de prestatie van de Hestia criteria wat betreft voorspellen 
van negatieve klinische uitkomsten vergeleken met de prestatie van de selectiemethode 
die geadviseerd wordt door de European Society of Cardiology (ESC). De ESC methode 
combineert hemodynamische status (bloeddruk en polsfrequentie) met de functie van de 
rechterventrikel van het hart om te bepalen of een patiënt met longembolie geschikt is 
voor thuisbehandeling. Tweeëntwintig patiënten (4.5%) die volgens de Hestia criteria in het 
ziekenhuis zijn behandeld hadden negatieve klinische uitkomsten in tegenstelling tot geen 
van de patiënten die geselecteerd waren voor thuisbehandeling (p<0.001). Sensitiviteit en 
negatief voorspellende waarde voor negatieve klinische uitkomsten waren respectievelijk 
100% voor de Hestia criteria en 83% en 98% voor de ESC criteria. Van de patiënten die thuis 
behandeld waren volgens de Hestia criteria, zou 34% niet thuis behandeld kunnen worden 
volgens de ESC criteria omdat ze rechterventrikeldisfunctie hadden. In de groep patiënten 
met rechterventrikeldisfunctie die volgens de Hestia criteria thuis zijn behandeld konden 
in de Hestia studie zijn geen negatieve klinische uitkomsten voorgekomen. Concluderend: 
klinische criteria als de Hestia criteria zouden gebruikt kunnen worden om patiënten, in-
clusief patiënten met rechterventrikeldisfunctie, met een laag risico op negatieve klinische 
uitkomsten te selecteren die in aanmerking komen voor thuisbehandeling. 
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Verhoogd NT-proBNP is een bekende risicofactor voor het optreden van negatieve kli-
nische uitkomsten bij patiënten met longembolie. Een eerdere studie heeft bewezen dat 
geselecteerde patiënten met een laag NT-proBNP veilig thuis behandeld kunnen worden. 
Wij hebben onderzocht of een herhaalde meting van NT-proBNP een groter percentage 
patiënten zou kunnen selecteren voor vervroegd ontslag of thuisbehandeling. De resultaten 
hiervan worden besproken in hoofdstuk 7. Het herhaald testen NT-proBNP binnen 48 uur 
leidde tot identificatie van 20% extra patiënten met een laag risico op negatieve uitkomsten, 
ten opzichte van het verrichten van één NT-proBNP test. 
Patiënten met een longembolie zonder een uitlokkende risicofactor hebben een hoger 
risico op verschillende soorten negatieve klinische uitkomsten, zoals niet-maligniteit gere-
lateerd overlijden, nieuw ontstane maligniteit en recidief VTE in vergelijking met patiënten 
die een longembolie uitgelokt door een risicofactor hebben. Dit is een van de conclusies die 
getrokken wordt in hoofdstuk 8. In dit hoofdstuk wordt tevens aangetoond dat slechts een 
deel van de patiënten in de jaren volgend op de longembolie geen negatieve uitkomsten 
heeft meegemaakt: 70% na één jaar, minder dan 60% na twee jaar en minder dan de helft na 
vier jaar. Dit in tegenstelling tot de controlepatiënten zonder longembolie, van wie 84% na 
vier jaar geen negatieve uitkomsten heeft gehad.
In hoofdstuk 9 wordt een additionele risicofactor voor een slecht klinisch beloop na 
longembolie besproken. Patiënten uit universitaire ziekenhuizen hadden een hoger risico 
op recidief VTE (3.3% vs. 2.6%; OR 1.3, 95% CI 0.50 - 3.3) en mortaliteit (9.0% vs. 6.9% OR 
1.3, 95% CI 0.75-2.4) dan patiënten uit perifere ziekenhuizen. Tevens hadden patiënten uit 
universitaire ziekenhuizen een tweemaal hoger risico op majeure bloedingen (4.3% vs. 2.2%; 
OR 2.0, 95% CI 0.77-5.1). De bloedingen waren sterk geassocieerd met de aanwezigheid van 
een actieve maligniteit ten tijde van het stellen van de diagnose longembolie (OR 3.4, 95%CI 
1.5-7.9). Onze gegevens laten zien dat patiënten met longembolie in universitaire ziekenhui-
zen verschillen van patiënten in perifere ziekenhuizen wat betreft patiëntkenmerken, zoals 
leeftijd en comorbiditeit, en klinische uitkomsten. Artsen moeten rekening houden met deze 
verschillen bij de interpretatie van resultaten van grote klinische studies en de toepassing 
van deze studies in de klinische praktijk.
Toekomstperspectieven 
Er komt steeds meer bewijs over de veiligheid van thuisbehandeling van patiënten met long-
embolie. De meest recente richtlijnen van het American College of Chest Physicians geven 
een aanbeveling van het niveau 2B over vervroegd ontslag uit het ziekenhuis van patiënten 
met longembolie. Voordat thuisbehandeling van patiënten met longembolie een aanbeve-
ling van niveau 1A krijgt, zal meer kwalitatief hoogstaand onderzoek nodig zijn. 
Zoals besproken is in dit proefschrift kan risicostratificatie van patiënten met longembolie 
gedaan worden met klinische criteria, biomarkers of meting van de rechterventrikelfunctie 
van het hart. Het huidige bewijs dat geleverd is door grote multicenter studies, waaronder 
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de Hestia studie, laat zien dat een geselecteerde groep laagrisico patiënten met longembolie 
thuis behandeld zou kunnen worden. Het moet echter nog blijken welke methode van 
risicostratificatie het meest veilig patiënten voor thuisbehandeling kan selecteren. Daarom 
moeten nieuwe onderzoeken, bij voorkeur gerandomiseerde studies, gedaan worden waarin 
verschillende manieren van risicostratificatie met elkaar vergeleken worden.
Een andere belangrijke verandering in de behandeling van patiënten met longembolie 
zal de introductie van de nieuwe orale anticoagulantia zijn. Voorbeelden van nieuwe orale 
anticoagulantia zijn de factor Xa- en trombineremmers. Op dit moment worden grote klini-
sche trials uitgevoerd naar de veiligheid en effectiviteit van deze middelen in de behandeling 
van longembolie. De introductie van de nieuwe anticoagulantia zou de thuisbehandeling 
van patiënten met longembolie kunnen vereenvoudigen, omdat bij de nieuwe anticoagu-
lantia, in tegenstelling tot vitamine K antagonisten, geen frequente laboratoriumcontroles 
uitgevoerd moeten te worden. Voordat de nieuwe orale anticoagulantia gebruikt kunnen 
worden voor thuisbehandeling van patiënten met longembolie, moet gegarandeerd worden 
dat patiënten, vooral in de eerste weken, goed gecontroleerd worden. In de toekomst moet 
nieuw prospectief onderzoek uitwijzen of thuisbehandeling van patiënten met longembolie 
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